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1. INTRODUCTION 
The newer drug delivery systems have been developed from time to time with a goal of 
providing the therapeutic amount of drug to the proper site in the body and to increase the 
bioavailability of the drug. An appropriately designed controlled-release drug delivery 
system can be major advance towards solving the major issues like delivering drug to the 
site, controlling the rate of drug delivery. This can be achieved by better control of 
plasma drug levels and less frequent dosing1.  
Historically, oral drug administration has been the predominant route for drug delivery. 
Oral dosage forms capable of having prolonged retention time in the stomach to extend 
the duration of drug delivery have been receiving much attention in recent years2.  More 
often, drug absorption is unsatisfactory and highly variable among and between 
individuals, despite excellent in vitro release patterns. The reasons for this are essentially 
physiological and usually affected by the GI transit of the form, especially its gastric 
residence time (GRT).3 
Over the past three decades, the pursuit and exploration of devices designed to be 
retained in the upper part of the gastrointestinal (GI) tract has advanced consistently in 
terms of technology and diversity, encompassing a variety of systems and devices.Gastric 
retention will provide advantages such as the delivery of drugs with narrow absorption 
windows in the small intestinal region. Also, longer residence time in the stomach could 
be advantageous for local action in the upper part of the small intestine, for example 
treatment of peptic ulcer disease. 
Furthermore, improved bioavailability is expected for drugs that are absorbed readily 
upon release in the GI tract. These drugs can be delivered ideally by slow release from 
the stomach. Many drugs categorized as once-a-day delivery have been demonstrated to 
have suboptimal absorption due to dependence on the transit time of the dosage form, 
making traditional extended release development challenging. Therefore, a system 
designed for longer gastric retention will extend the release time .4 
Drugs that are having short half-lives are eliminated quickly from the systemic 
circulation. In order to achieve suitable therapeutic activity, the drug should be 
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administered frequently. This can be overcome by developing the drug in to controlled 
release formulations which will release the drug slowly into the gastrointestinal tract 
(GIT). This approachwill maintain an effective drug concentration in the systemic 
circulation for a longer durations. Thus the orally administered controlled drug will 
retained in the stomach and release the drug in a controlled manner supply the drug 
continuously to its absorption sites of the gastrointestinal tract (GIT) 5. 
1.1 GASTRORETENTIVE DRUG DELIVERY SYSTEMS 
Gastroretentive drug delivery is an approach to prolong gastric residence time, thereby 
targeting site-specific drug release in the upper gastrointestinal tract (GIT) for local or 
systemic effects. Gastroretentive dosage forms can remain in the gastric region for long 
periods and hence significantly prolong the gastric retention time (GRT) of drugs. 
      1.1.1 Advantages6 
 Improvement of bioavailability and therapeutic efficacy of the drugs and possible  
dose reduction e.g. Furosemide 
 Enable constant therapeutic levelsover a prolonged period and thus reduction in 
fluctuation in therapeutic levels minimizing the risk of resistance especially in 
case of antibiotics. E.g. b-lactam antibiotics (penicillin and cephalosporins) 
 For drugs with relatively short half-life, sustained release may result in a flip- flop 
pharmacokinetics and also enable reduced frequency of dosing with improved 
patient Compliance. 
 They also have an advantage over their conventional system as it can be used to 
overcome the adversities of the gastric retention time (GRT) as well as the gastric 
emptying time (GET). As these systems are expected to remain buoyant on the 
gastric fluid without affecting the intrinsic rate of employing because of their bulk 
density is lower than that of the gastric fluids. 
 Gastro retentive drug delivery can produce prolongs and sustains release of drugs from 
dosage forms which avail local therapy in the stomach and small intestine. Hence they are 
useful in the treatment of disorders related to stomach and small intestine. 
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 The controlled, slow delivery of drug form gastro retentive dosage form provides 
sufficient local action at the diseased site, thus minimizing or eliminating systemic 
exposure of drugs. This site-specific drug delivery reduces undesirable side effects. 
 Gastro retentive drug delivery can minimize the counter activity of the body leading to 
higher drug efficiency. 
 Reduction of fluctuation in drug concentration makes it possible to obtain improved 
selectivity in receptor activation. 
 The sustained mode of drug release from Gastro retentive doses form enables extension of 
the time over a critical concentration and thus enhances the pharmacological effects and 
improves the chemical outcomes. 
 
1.1.2 NECESSITIES OF A DRUG FOR GASTRIC RETENTION7: 
1. Physiological factors in the stomach,  
2. The dosage form must be able to withstand the forces caused by peristaltic waves in the 
stomach and the constant contractions and grinding and churning mechanisms. 
3. To function as a gastric retention device, it must resist premature gastric emptying.  
4. Furthermore, once its purpose has been served, the device should be removed from the 
stomach with ease. 
 1.1.3 LIMITATIONS OF GASTRO RETENTION8: 
1. The floating systems in patients with achlorhydria can be questionable in case of 
swellable systems, faster swelling properties are required and complete swelling of the 
system should be achieved well before the gastric emptying time. 
2.  high turnover of mucus may affect  the effectiveness of gastro retention 
3. retention of high density systems in the antrum part under the migrating waves of the 
stomach is questionable. 
4. Not suitable for drugs that may cause gastric lesions e.g. Non- steroidal anti 
inflammatory   drugs. Drugs that are unstable in the strong acidic environment, these 
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systems do not   offer significant  advantages over the conventional dosage forms for 
drugs, that are  absorbed throughout the gastrointestinal  tract. 
5. The mucus on the walls of the stomach is in a state of constant renewal, resulting in 
unpredictable adherence. 
6. In all the above systems the physical integrity of the system is very  important and 
  Primary requirement for the success of these systems 
1.1.4 Factors Affecting Gastric Retention:10 
 Density: GRT is a function of dosage form buoyancy that is dependent on  the density. 
 Size: Dosage form units with a diameter of more than 7.5mm are reported to have 
anIncreased GRT compared with those with a diameter of 9.9mm. 
 Shape of dosage form:  Tetrahedron and ring shaped devices with a flexural 
modulusof  48 and 22.5 kilo pounds per square inch  (KSI) are reported to have 
betterGRT≈90% to 100% retention at 24 hours compared with other shapes. 
 Single or multiple unit formulation: Multiple unit formulations show a 
morePredictable   release profile and insignificant impairing of performance due to 
failure of units, allow co- administration of units with different release profiles or 
containing incompatible substances and permit a larger margin of safety against 
dosage form failure compared  with single unit dosage forms. 
 Fed or unfed state: under fasting conditions:  GI motility is characterized by 
periodsof strong motor activity or the migrating myoelectric complex (MMC) that 
occursevery 1.5 to 2 hours. The MMC sweeps undigested material from the stomach 
and, if thetiming of  administration of the formulation coincides with that of the MMC, 
the GRTof the unit can   be expected to be very short. However, in the fed state, MMC 
is delayedand GRT is  considerably longer. 
 Nature of meal: feeding of indigestible polymers or fatty acid salts can change 
themotility pattern of the stomach to a fed state, thus decreasing the gastric emptying 
rateand  prolonging drug release. 
 Caloric content: GRT can be increased by 4 to 10 hours with a meal that is high 
in   proteins and fats.  
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 Frequency of feed: the GRT can increase by over 400 minutes,  when successive meals 
are given compared with a single meal due to the low  frequency of MMC. 
 Gender:  Mean ambulatory GRT in males (3.4±0.6 hours) is less compared with their  age 
 and race matched female counterparts (4.6±1.2 hours), regardless of the weight,  height 
and   body surface. 
 Age: Elderly people, especially those over 70, have a significantly longer GRT. 
 Posture: GRT can vary between supine and upright ambulatory states of the patient. 
 Concomitant drug administration: Anticholinergics like atropine and propantheline, 
opiates like codeine and prokinetic agents like metoclopramide  and cisapride. 
 Biological factors: Diabetes and Crohn’s disease. 
 
1.1.5. DRUG CANDIDATES SUITABLE FOR GASTRORETENTIVE 
DRUG DELIVERY SYSTEM12 
a. Drugs which act primarily in the stomach. E.g. antacids. 
b. Drugs that are primarily absorbed from the stomach. E.g. amoxicillin 
c. Drugs that are poorly soluble at alkaline pH. E.g. verapamil, diazepam, etc. 
d. Drugs with a narrow window of absorption. E.g. levodopa, cyclosporine, etc. 
e. Drugs which are rapidly absorbed from the GIT. E.g. tetracycline  
f. Drugs that degrade in the colon. E.g. ranitidine, metformin, etc. 
g. Drugs that disturb normal colonic microbes. E.g. Antibiotics against Helicobacter pylori. 
1.1.6. Drug candidates unsuitable for gastroretentive drug delivery system13 
a. Drugs that have very limited acid solubility e.g. phenytoin etc. 
b. Drugs that suffer instability in the gastric environment e.g. erythromycin etc. 
c. Drugs intended for selective release in the colon e.g. 5- amino salicylic acid and 
corticosteroids etc. 
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1.1.7 Approaches for gastro retention14,15,16: 
 To improve the retention of an oral dosage form in the stomach various approaches have 
been developed, it includes floating systems and non-floating systems. Floating systems 
includes effervescent systems and non-effervescent systems, these systems have the bulk 
density lower than the gastric fluid and remain floating and releases the drug slowly in a 
desired rate. Non floating systems include bioadhesive systems, swelling systems, high 
densitysystems, expandable systems, raft forming systems, magnetic systems which 
utilizedifferent mechanisms to prevent the exit of drugs through pyloric sphincters. 
1.2 TYPES OF GASTRO-RETENTIVE DRUG DELIVERY SYSTEMS 
The various types of gastro retentive drug delivery systems are basically classified in to 
two major classes based on the floating efficiency. 
I.  Floating systems 
 A. Effervescent systems 
              1. Volatile liquid containing systems 
  a. Intra gastric floating gastrointestinal drug delivery system  
                          b.Inflatable gastrointestinal drug delivery systems 
c. Intra gastric osmotically controlled drug delivery systems 
 
 
  2. Gas generating systems  
a. floating capsules  
b. floating pills 
c. Floating system with ion exchange resins 
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B. I. Non – effervescent systems 
1. Hydro dynamically balanced systems 
2. Microballons/ microspheres 
3. Alginate beads 
4. Matrix layered tablets 
5. Raft forming systems  
II. Non floating systems  
A. Swelling systems  
B. Magnetic systems 
C. Expandable systems 
D. High density systems 
1.2.1. FLOATING DRUG DELIVERY SYSTEMS 17: 
These are the low density systems having the bulk density less than the gastric fluids and 
thus remain buoyant in the stomach without affecting the gastric emptying rate for a 
prolonged period of time. When the drug delivery system is floating on the gastric contents, 
the drug is released slowly at the desired rate from the system. This results in increased 
gastro retention time and a better control of fluctuations in the plasma drug concentration. 
Based on the buoyancy mechanism, floating systems are classified as follows 
A. Effervescent systems 
B.Non effervescent systems 
A. Effervescent systems18 
These dosage forms are developed in such a way that, when they come in contact with 
gastric juices in the stomach , carbon dioxide gas is released due the reaction between 
sodium bicarbonate, citric acid and tartaric acid and is trapped in the swollen hydrocolloids. 
This provides buoyancy to the dosage form there by making it to float on the gastric fluids. 
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These systems may also contain liquids which gasify and evaporates at body temperature 
by which the specific gravity decreases and causes the dosage form to float.  
These effervescent systems have been further classified into different types: 
1) Volatile liquid containing systems19: These are further classified as  
a) Intragastric floating gastrointestinal drug delivery systems: These systems are 
made to Float in the stomach because of the floating chamber, which may be filled with 
air or vacuum or harmless gas, and the drug reservoir is encapsulated inside a micro 
porous compartment. This micro porous compartment has pores on the top and bottom 
surfaces, whereas the peripheral walls of the reservoir compartment were completely 
sealed to prevent any physical contact of the undissolved drug with the walls of the 
stomach. 
b) Inflatable gastrointestinal drug delivery system: These systems consist of inflatable 
chamber with liquid ether that gasifies at body temperature making the chamber to inflate 
in the stomach. This inflatable chamber contains a drug reservoir which is encapsulated in 
a gelatin capsule. After oral administration, the capsule dissolves and releases the drug 
reservoir together with the inflatable. 
c) Intragastric osmotically controlled drug delivery system: 
It consists of osmotic pressure controlled drug delivery device and an inflatable support in 
a biodegradable capsule. On reaching the stomach, inflatable capsule disintegrates and 
releases the osmotically controlled drug delivery. The inflatable support inside forms a 
deformable hollow polymeric bag that contains a liquid that gasifies at body temperature 
to inflate the bag. Osmotic pressure controlled drug delivery device consists of two 
components i.e. drug reservoir compartment and osmotically active compartment. The 
drug reservoir compartment is enclosed in a pressure responsive collapsible bag, which is 
impermeable to vapour and liquid and it contains a delivery orifice. The osmotically active 
compartment consists of a semi permeable membrane which encloses osmotically active 
salt. This device on reaching the stomach absorbs water from the gastro intestinal fluids 
through the semi permeable membrane into the osmotically active compartment and 
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dissolves the osmotically active salt and creates the osmotic pressure. The pressure 
developed acts on the collapsible bag which forces the drug reservoir compartment to 
activate the release of drug in the solution form through the delivery orifice. After the 
predetermined period of time the biodegradable plug in the floating support erodes and 
deflates the support, which is then emptied from the stomach 
Gas generating systems20: In these systems floatability is achieved by generation of gas 
bubbles.  Carbon dioxide is generated in situ by incorporation of carbonates or 
bicarbonates, which react with acid, either the natural gastric acid or co-formulated as 
citric or tartaric acids. The gas generated makes the systems to float on the gastric fluids 
and releases the drug at a predetermined rate. These are of different types  
        a. Floating capsules: Floating capsules are prepared by filling a mixture of sodium 
alginate and sodium bicarbonate, these float due to the generation of carbon dioxide which 
gets trapped in the hydrating gel network on exposure to an acidic environment. 
        b. Floating pills:These systems consist of two layers, inner effervescent layer 
containing       sodium   bicarbonate and tartaric acid and the outer swellable polymeric 
membrane. The inner layer is further divided into two sub layers to avoid physical contact 
between sodium bicarbonate and tartaric acid. When this pill is immersed in buffer 
solution at 37 °C, it settles down at the bottom and buffer solution enters into the 
effervescent layer through the outer Swellable membrane. Swollen pills or balloons are 
formed due the generation of carbon dioxide as a result of reaction between sodium 
bicarbonates and tartaric acid. The carbon dioxide generated is entrapped within the 
delivery system making the device to float.  
These systems were found to float completely within 10 minutes and have good floating 
ability independent of pH, viscosity of the medium and the drug is released in a controlled 
manner. 
c. Floating systems with ion exchange resins: These systems are formulated by using 
ion exchange resin that is loaded with bicarbonate by mixing the beads with sodium 
bicarbonate solution .These loaded beads were then surrounded by a semi permeable 
membrane to avoid the sudden loss of carbon dioxide. Upon coming in contact with 
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gastric contents there is an exchange of chloride and bicarbonate ions resulting in 
generation of carbon dioxide thereby carrying beads toward the top of gastric contents and 
producing a floating layer of resin beads, which releases the drug at a predetermined. 
B .Non effervescent systems21: Non effervescent drug delivery systems are those which 
upon swallowing swells via imbibition of gastric fluids to an extent that it prevents their 
exit from the stomach. These systems may also be referred to as ‘plug-type systems’ 
since they have the tendency to remain lodged near the pyloric sphincter. Different types 
of non effervescent systems area. Hydrodynamic ally balanced systems (HBS): HBS are 
also called as ‘colloidal barrier systems’ these systems contains drug along with thegel 
forming hydrocolloids. When thecapsules containing the drughydrocolloid mixture 
comes in contact with the gastric fluids, the capsule shell dissolves and the mixture 
swells to form a gelatinous barrier, which imparts buoyancy in gastric fluids for a 
prolonged period of time due to the continuous erosion of the surface. This allows water 
penetration in to the inner layers maintaining surface hydration and buoyancy to the 
dosage form. This gel barrier controls the rate of fluid penetration into the device and 
consequent release of drug from the system. 
1.Microballoons / hollow microspheres22: Micro balloons/ hollow 
microspheres are the lowdensity systems that have sufficient buoyancy to float over 
gastric contents and remain in stomach for prolonged period. These systems contain 
outer polymer shell loaded with drug. When they come in contact with gastric fluid 
the gel formers, and polymers hydrate to form a colloidal gel barrier that controls the 
rate of fluid penetration into the device and consequent drug release. As the exterior 
surface of the dosage form dissolves, the gel layer is maintained by the hydration of 
the adjacent hydrocolloid layer. The airtrapped by the swollen polymer lowers the 
density and confers buoyancy to the microspheres. These are considered as one of the 
most promising buoyant systems as they possess the unique advantage of multiple 
unit system as well as better floating properties because of central hollow space inside 
the microspheres. 
2.Alginate beads: These are the freeze-dried calcium alginate beads of 
approximately 2.5 mm diameter prepared by dropping sodium alginate solution into 
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aqueous solution of calcium chloride, causing precipitation of calcium alginate 
leading to formation of porous system, which helps in floating of  
the system on the gastric contents. Due to the porous nature these can maintain a 
floating force for over 12 hours. When compared with solid beads, which gave a short 
residence time of 1 hour, and these floating beads shows a prolonged residence time 
of more than 5.5 hours. 
3.Matrix layered tablets23: These are the dosage forms which contain gel forming 
hydrocolloids which make the delivery system to float on the gastric contents. These 
may be single layered, bi layered and tri layered. 
i. Single layered matrix tablets are obtained by intimate mixing of drug with gel 
forming hydrocolloids which swells in contact with gastric fluids and maintains bulk 
density less than gastric fluids. 
ii. Bi layered tablets contain one immediate release layer and one sustained release 
layer. Immediate release layer releases the initial dose of drug and the sustain release 
layer absorbs the gastric fluids and produces the bulk density of less than that of GI 
fluids and remain in stomach for an extended period of time. 
iii. Tri layered tablets consists of immediate release layer, sustained release layer and 
the gas generating layer, which helps the system to float.  
4. Raft forming systems24: These systems contains a gel forming agent and alkaline 
bicarbonates or carbonates responsible for the formation of carbon dioxide to make 
the system less dense and float on the gastric fluid. The mechanism involved in the 
raft formation includes the formation of viscous cohesive gel on contact with gastric 
fluids, where in each portion of the liquid swells forming a continuous layer called as 
raft. This raft floats on gastric fluids and prevent the reflux of the gastric contents into 
esophagus by acting as a barrier between stomach and esophagus, thus these systems 
have received much attention for the delivery of antacids and drug delivery for 
gastrointestinal infections and disorders. 
1.2.2.Non Floating drug deliverysystems25: 
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These are the drug delivery systems which do not float but remain in the stomach for 
prolonged period of time. Different mechanism have been used to retain the device in 
the stomach which includes  
A. Bioadhesive systems: The term bioadhesion is defined as adhesion of the delivery 
system to biological surface i.e. mucus and/or mucosal surface. Bioadhesive systems 
adhere to the mucosa of the stomach and remain in intimate contact with the 
membrane for longer period of time and hence retains in the stomach for its 
prolonged release. Bioadhesive polymers are used to formulate these systems.  
B. Swelling system: Gastro retentivity of the dosage form can be enhanced by 
increasing its size above the diameter of the pylorus. Thus, thesedelivery system are 
formulated with swellable polymers which upon entering the stomach causes these 
polymers to swells to an extent the device cannot pass through the pyloric sphincter 
leading to the retention of the delivery device in stomach.  
C.High density systems: These are the systems which have the density greater than 
the density of the gastric fluids as a result these systems sinks to the bottom of the 
stomach, thus retains in the stomach for prolonged period of time. These are usually 
formulated by coating the drug on heavy inert materials like zinc oxide, titanium 
dioxide, iron powder etc. 
D. Expandable / unfolded systems26, 27: In these systems the size of the delivery 
system is increased beyond the diameter of pylorus there by the gastro retentive 
activity of the dosage form is achieved. Thus expandable or unfolded drug delivery 
systems were developed. These dosage forms are usually small enough to be 
swallowed. In the stomach after coming in contact with the gastric fluids, they get 
expanded to a larger size so that gastric retention is achieved. In these systems 
compressed systems are placed in the carriers such as capsules and then administered, 
upon contact with gastric fluid, these systems get unfolded into the forms which can 
retain in the stomach for longer time. 
E.Magnetic systems: These are designed in such a way that the dosage form 
contains a small internal magnet. After the administration of the dosage for, a 
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small magnet is placed on the abdomen over the position of the stomach. By this 
technique the dosage form with an internal magnet is retained in the stomach 
region until the external magnet remains. 
 
1.3.MUCOADHESIVE APPROACH FOR GASTRO RETENTION  
Mucoadhesion can be defined as a state in which two components, of which one is of 
biological origin are held together for extended periods of time by the help of interfacial 
forces. Mucoadhesion is a complex phenomenon which involves wetting, adsorption and 
interpenetration of polymer chains. 
ADVANTAGES 
i. Improved patient compliance,  
ii. Improved Drug compliance,  
iii. Better control of disease condition,  
iv. Better  control of plasma levels,  
v. Decreasing in total amount of dose administered,  
vi. Short time require for disease treatment,  
vii. Reducing in health care costs. 
Several research groups have been reported different gastro intestinal mucoadhesive dosage 
forms such as microspheres, matrix tablets, discs etc28. 
1.4.TYPESOF BIO ADHESION9 
The term bioadhesion refers to any bond formed between two biological surfaces or a bond 
between a biological and a synthetic surface. In case of bioadhesive drug delivery, the term 
bioadhesion is used to describe the adhesion between polymers, either synthetic or natural 
and soft tissues or the gastrointestinal mucosa. In cases where the bond is formed with the 
mucus the term mucoadhesion may be used synonymously with bioadhesion.  
 Type I:Type I Bioadhesion is characterized by adhesion occurring between biological 
objects without involvement of artificial materials.  
Example: Cell fusion and cell aggregation 
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 Type II:Type II Bioadhesion can be represented by cell adhesion onto culture dishes or 
adhesion to a variety of substances including metals, woods, and other synthetic 
materials. 
 Type III:Type III Bioadhesion can be described as adhesion of artificial substances to 
biological substrates such as adhesion of polymers to skin or other soft tissues. 
 
1.5. MECHANISM OF MUCOADHESION  
Mucoadhesion is the attachment of the drug along with a suitable carrier to the mucous 
membrane. Mucoadhesion is a complex phenomenon which involves wetting, 
adsorption and interpenetration of polymer chains. Mucoadhesion has the following 
mechanism.29 
1. Intimate contact between a bioadhesive and a membrane (wetting or swelling 
Phenomenon) 30, 31 
2. Penetration of the bioadhesive into the tissue or into the surface of the mucous 
membrane    (interpenetration)30,31 
1.6. THEORIES OF MUCOADHESION29 
1. Wetting Theory: 
   Wetting theory is predominantly applicable to liquid bioadhesive systems. It 
analyzes adhesive and contact behavior in terms of the ability of a liquid or paste to 
spread over a biological system. The work of adhesion expressed in terms of surface and 
interfacial tension, Y, is defined as the energy per square centimeter released when an 
interface is formed. 
The work of adhesion is given by: 
Wa = YA + YB - YAB 
Where, A and B refer to the biological membrane and the bioadhesive 
formulation respectively. The work of cohesion is given by: 
WC = 2YA or YB 
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For a bioadhesive material B spreading on a biological substrate A, the spreading 
coefficient is given by: 
SB/A = YA – (YB + YAB) 
SB/A should be positive for a bioadhesive material to adhere to a biological 
membrane. 
 
2. Electronic theory:  
The electronic theory depends on the assumption that the bioadhesive material and  
the target biological material have different electronic surface characteristics. Based on 
this,  
when two surfaces come in contact with each other, electron transfer occurs in an 
attempt to  
balance the Fermi levels, resulting in the formation of a double layer of electrical charge 
at 
the interface of the bioadhesive and the biologic surface. The bioadhesive force is 
believed to be present due to the attractive forces across this double layer.32, 33 
3.Fracture Theory: 
Fracture theory attempts to relate the difficulty of separation of two surfaces after 
adhesion. Fracture theory equivalent to adhesive strength is given by: 
G = (E/L) l h 
Where, E is the Young’s modulus of elasticity 6 is the fracture energy, and L is 
the critical crack length when two surfaces are separated. 
4. Adsorption theory:  
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This theory states that the bioadhesive bond formed between an adhesive 
substrate and the tissue is due to the weak van der waals forces and hydrogen bond 
formation. It is one of the most widely accepted theories of bioadhesion.34,35 
1.7. POLYMERS USED IN THE MUCOADHESIVE DRUG DELIVERY 
SYSTEMS 
A.NATURAL POLYMERS: 
Examples: Na alginate, Pectin, Tragacanth, Gelatin, Carrageenan, Gum karaya, Gum 
ghatti 
B.SYNTHETIC POLYMERS: 
Examples: Polyvinyl alcohol, Polyamides, polycarbonates, Polyalkylene glycols, 
polyvinyl esters. Esters and halides, Polymethacrylic acid, Polymethyl methacrylic acid. 
Methylcellulose, Ethylcellulose, Hydroxypropyl cellulose, hydroxy propyl 
methylcellulose. Sodiumcarboxymethylcellulose. 
 
 
 
C.BIODEGRADABLE POLYMERS: 
Examples: Poly (lactides), Poly (glycolides), Poly (lactides-co-glycolides), 
Polycaprolactones. Polyalkyl cynoacrylates, Polyorthoestes, Polyphosphoesters, 
Polyanhydrids. Polyphosphaznes Chitosan, Polyethylene oxide. 
D.BIOCOMPATIBLE POLYMERS: 
Examples: Esters of hyaluronic acid. Polyvinyl acetate, Ethylene glycol 
Ideal Properties of a mucoadhesive polymer36 
 Not binding covalently with the mucus layer. 
 Possess high chain flexibility.  
 It must be loaded substantially by the active compound. 
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 Swell in the aqueous biological environment of the delivery–absorption site. 
 Interact with mucus or its components for adequate adhesion.  
 When swelled they allow, controlled release of the active compound. 
  To be excreted unaltered or biologically degraded to inactive metabolites. 
1.8. DIABETES MELLITUS 
Diabetes mellitus (DM) is a metabolic disorder resulting from a defect in insulin 
secretion, insulin action, or both. Insulin deficiency in turn leads to chronic 
hyperglycemia with disturbances of carbohydrate, fat and protein metabolism.37It is one 
of the most common metabolic syndromes, since there are 200 million diabetic 
individuals in the world. 
 Several pathogenic processes are involved in the development of diabetes; these 
range from autoimmune destruction of the cells of the pancreas with consequent insulin 
deficiency to abnormalities that result in resistance to insulin action. Deficient action of 
insulin on target tissues and hyperglycemia are the basis of the abnormalities in 
carbohydrate, fat, and protein metabolism, causing diabetes ’characteristic clinical 
features, micro and-macro vascular complications and Increased risk of cardiovascular 
disease 38. 
 
 
 
 
1.8.1 CLASSIFICATION OF DIABETES 
The new classification system (American Diabetes Association 2004) identifies 
four types of diabetes mellitus:  
1. TYPE 1,  
         2.TYPE 2,  
        3.GESTATIONAL DIABETES. 
4.OTHER SPECIFIC TYPES  
 
1.8.1.1. TYPE 1 DIABETES MELLITUS (INSULIN DEPENDENT DIABETES 
MELLITUS) 
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Type 1 diabetes mellitus (T1D) is characterized by ȕ-cell destruction caused by an 
autoimmune process, usually leading to absolute insulin deficiency (39,40). This form of 
diabetes, which accounts for only 5–10% of all diabetes, is a juvenile-onset diabetes; it 
results from a cellular-mediated autoimmune destruction of the ȕ-cells of the pancreas by 
CD4 and CD8 T cells and macrophages infiltrating the islets. 
 In this case insulin therapy is required for survival, to prevent the development of 
ketoacidosis, coma and death41. 
 
1.8.1.2. TYPE 2 DIABETES MELLITUS (NON-INSULIN DEPENDENT DIABETES 
MELLITUS) 
Type 2 Diabetes Mellitus (T2D) is a complex heterogeneous group of metabolic 
condition characterized by elevated levels of serum glucose; according to WHO, it is 
defined as resulting from a defect in both insulin secretion and in insulin sensitivity.ȕ-cell 
dysfunction includes abnormalities in pulsatility and in kinetics of insulin secretion, 
quantitative and qualitative abnormalities of insulin, ȕ-cell loss and its progression. 
Type 2 Diabetes exerts a huge toll in human suffering and economy. The total 
number of people with diabetes is projected to rise from 171million in 2000 to 366 
million in 2030, with India, China and USA being the top 3countries estimated to have 
the highest numbers of people with diabetes (42,43,44). 
 
1.8.1.3. GESTATIONAL DIABETES. (45,46) 
Gestational Diabetes (GD) mellitus refers to the onset or initial recognition of glucose 
intolerance during pregnancy, usually in the second or third trimester. It occurs in 
about4% of all pregnancies. Patients with GD have a 30% to 50%chance of developing 
DM, usually  
Type 2 DM. 
 
1.8.1.4. OTHER SPECIFIC TYPES (48,49) 
 
 Genetic defects of ß-cell function 
 Genetic defects in insulin secretion 
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 Diseases of the exocrine pancreas 
 Endocrinopathies 
 Drug-induced or chemical induced 
 Infections (congenital rubella, cytomegalovirus and others) 
 Uncommon forms of immune mediated diabetes 
 Other genetic syndromes sometimes associated with 
 Diabetes Gestational diabetes 
1.8.2.ETIOLOGY (49) 
Type 1 Diabetes 
 Caused by the immune destruction of the beta cells of the pancreas. 
 Antibodies to islet cells and insulin are present at diagnosis. 
 Insulin secretion gradually diminishes. 
 May present at any age, but most common in childhood and adolescence. 
 Insulin by injection is necessary for survival. 
 
Other factors 
o Genetic  
o Environmental triggers (infection or other stress) 
Type 2 Diabetes 
 Caused by insulin resistance in the liver and skeletal muscle, increased glucose 
production in the liver 
 Over production of free fatty acids by fat cells and relative insulin deficiency. 
 Insulin secretion decreases with gradual beta cell failure. 
 Reductions in blood glucose levels often can be achieved with changes in food 
intake and 
 Physical activity patterns. Oral medication and/or insulin injections are eventually 
required. 
 Contributing factors: 
o Obesity 
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o Age (onset of puberty is associated with increased insulin resistance) 
o Lack of physical activity 
o Genetic predisposition 
o Racial/ethnic background (African American, Native American, Hispanic and 
Asian/PacificIslander) 
o Conditions associated with insulin resistance, (e.g., polycystic ovary syndrome) 
1.8.3.SYMPTOMS OF DIABETES 
 Polyuria 
 Polydipsia 
 Polyphagia 
 Blurred vision 
 genital itching 
 slow wound healing 
 weight loss 
1.8.4. TREATMENT  
   The major components of the treatment of diabetes are: 
 insulin treatment  
 oral hypoglycemic therapy sa 
 diet (combined with exercise if possible) 
DRUGS USED IN TREATMENT50 
There are many drugs used in the treatment of diabetes mellitus such as  
 Sulfonylureas: Tolbutamide, Chlorpropamide, Gliclazide, Glipizide, and 
Glibenclamide. 
 Bigunides: Metformine, Phenformine, 
 Meglitinide analogues: Repaglinide, Nateglinide, 
 α Glucosidase inhibitors: Acarbose, Miglitol and many others. 
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1.9. Anatomy and physiology of gastrointestinal tract. 
1.9.1. Anatomy of the gastrointestinal tract51, 52: 
The gastrointestinal tract categorizes into three mainparts: 
a. Stomach 
b. Small intestine- Duodenum, Jejunum and Ileum 
c. Large intestine 
The gastrointestinal tract is a long muscular tube, startingfrom the mouth and end at the 
anus, which capture thenutrients inside the body and eliminate waste by 
differentphysiological processes such as secretion, digestion,absorption and excretion. 
Figure 1 includes the basicconstruction of gastrointestinal tract from stomach tolarge 
intestine. 
The stomach is a J-shaped organ which can be dividedinto four parts: cardia, fundus, body 
and antrum. Themain function of the stomach is to store and mix foodwith gastric 
secretions. 
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Figure no: 1.1: Anatomy of gastroretentive tract 
 
1.9.1.1.Layers of the GI Tract 
The GI tract is composed of four layers or also known as Tunics. Each layer has 
different tissues and functions. From the inside out they are called:  
i. mucosa,  
ii. submucosa,  
iii. muscularis, 
iv. Serosa. 
Mucosa: The mucosa is the absorptive and secretory layer. It is composed of simple 
epithelium cells and a thinconnective tissue. There are specialized goblet cells that 
secrete mucus throughout the GI tract located within themucosa. On the mucosa layer 
there are Villi and Micro Villi. 
 
Submucosa: The submucosa is relatively thick, highly vascular, and serves the mucosa. 
The absorbed elements thatpass through the mucosa are picked up from the blood 
vessels of the submucosa. The submucosa also has glands andnerve plexuses. 
 
Muscularis: The muscularis is responsible for segmental contractions and peristaltic 
movement in the GI tract. The Muscularis is composed of two layers of muscle: an inner 
circular and outer longitudinal layer of smooth muscle.These muscles cause food to 
move and churn with digestive enzymes down the GI tract. 
 
Serosa: The last layer is a protective layer. It is composed of avascular connective tissue 
and simple squamousepithelium. It secretes lubricating serous fluid. This is the visible 
layer on the outside of the organs. 
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Fig.no. 1.2 Layers of Stomach 
 
1.9.1.2 Physiology of gastrointestinal tract: 
The stomach anatomy is mainly consists of 3 regions;fundus, body, and antrum pylorus. 
The proximal part ismade up of fundus and body. It serves as a reservoir forthe 
materials which remain undigested, whereas theantrum is the main site for mixing 
motions and acts as apump for gastric emptying by propelling actions. Gastricemptying 
occurs during both fasting as well as fed states.The pattern of motility is distinguished in 
2 states. During the fasting state an interdigestive series of electricalevents takes place, 
which cycles through stomach and intestine every 2 to 3 hours.This is called 
theinterdigestive myloelectric cycle or migrating myloelectric Cycle (MMC),which is 
further divided into following 4phases53. 
                      
Figure no 1.3: A simplified schematic diagram of the interdigestive balanced 
motility pattern. 
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1. Phase I (basal phase) - lasts from 40 to 60 minutes with rate contractions. 
2. Phase II (preburst phase) - lasts for 40 to 60 minutes with intermittent action 
potential 
andcontractions. As the phase progresses, the intensity and frequency also increase 
gradually. 
3. Phase III (burst phase) - lasts for 4 to 6 minutes. It includes intense and regular 
contraction for short period. It is due to this wave that all the undigested material is 
swept out the stomach down to the small intestine. It is also known as the housekeeper 
wave. 
4. Phase IV- lasts for 0 to 5 minutes and occurs between phases III and 1 to 2 
consecutive cycles. 
 1.9.1.3Determining Gastric Emptying Rates    
Ȗ- scintigraphy, radiology, endoscopy, ultrasonography, radio telemetry and magnetic 
marker monitoring studies have been applied to determining gastric emptying rates 
revealed that orally administered controlled release dosage forms are subjected to 
basically two complications that of short gastric residence time and unpredictable 
gastric emptying rate54. 
Drugs that areeasily absorbed from gastrointestinal tract (GIT) and with short half-
lives are eliminated quicklyfrom the systemic circulation. Repeated dosingof these 
drugs is required to achieve suitabletherapeutic activity. To avoid this limitation, the 
development of oral sustained-controlledrelease formulations is an attempt to release 
thedrug slowly into the gastrointestinal tract (GIT)and maintain an effective drug 
concentration inthe systemic circulation for a long time. 
In our present researchwe have selected Gliclazide as a project drug because of its 
demerits when administered as a conventional dosage form. The demerits of such a 
dosage form are 
 Frequent dosing. 
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 Low bioavailability of drug. 
These drawbacks can be overcome by the use of gastro retentive mucoadhesive 
tablets. The expected advantages are like, 
 Bioavailability of drug can be improved. 
 It can also reduce frequent dosing. 
 It can increase gastric emptying time. 
 It can increase gastric retention time. 
To prepare these mucoadhesive gastroretentive tablets commonly available natural 
polymers like chitosan, xanthan gum, gum obtained from Moringa Oleifera(moringa 
gum) were selected. The drug and the polymers are subjected to compatibility studies, 
evaluated for powder properties and prepared by direct compression method. The 
compressed tablets are evaluated for the pharmacopeia parameters and stability tests 
were carried out for the optimized formulations.  
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2. LITERATURE REVIEW 
2.1. Past work done on gliclazide 
 Kumar et al (2010), developed microsphere of gliclazide by using natural polymer. 
Gliclazide microspheres with a coat consisting of alginate and gum kondu gogu were 
prepared by orifice-ionic gelation method and emulsification gelation technique. The 
encapsulation efficiency was found around 86.23 % ± 0.56 to 94.46 % ± 0.86 and % drug 
content is in the range 55 ± 0.65 % - 68 ± 0.86 %, drug release from the microsphere was 
found slow, followed zero-order release kinetics with non-fickian release mechanism stating 
release depended on the coat: core and the method employed in preparation in microsphere55. 
 
 Patil et al (2009), developed mucoadhesive microcapsule of gliclazide. Depending 
upon the variability in the concentration of alginate, percentage of cross linking agent, time 
of curing, the factors like particle size, incorporation efficiency and release rate of 
microcapsules varies. The microcapsules obtained were discrete, spherical and free flowing. 
The microcapsules coated with mucoadhesive polymer chitosan exhibited good 
mucoadhesive property in the in vitro wash off test and also showed high percentage drug 
entrapment efficiency. The swelling behavior was strongly depends upon chitosan 
concentration. The in vitro release studyindicates that the swelling is the main parameter in 
controlling the release rate from microcapsules56. 
 
 Kumar et al (2010), developed fast dissolving tablets of gliclazide. The prepared 
batches of tablets were evaluated for hardness, friability, and weight variation, disintegration, 
wetting time, drug content and in vitro dissolution studies. Based on evaluating parameters, 
Formulation prepared by using 5% croscarmellose sodium with 3% PVP K30 was selected as 
optimized formulation. Finally, the optimized formulation was compared with marketed 
conventional formulation. Stability studies were carried out at 25ºC / 60% RH and 40ºC / 
75% RH for optimized formulation for 2 months. Stability studies on the optimized 
formulation indicated that there was no significant change found in physical appearance, 
disintegration time and wetting time of the tablets57. 
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 Nayak et al (2010), developed mucoadhesive beads of gliclazide. The mucoadhesive 
beads were characterized for entrapment efficiency, particle size, surface morphology, and 
swelling index. The kinetics of drug release and their mucoadhesive nature in vitro using 
goat intestinal mucosa was also investigated at various physiological pH conditions. The 
effective mucoadhesion property with sustained release profile was observed from optimized 
mucoadhesive beads consisting of alginate and ispaghula husk (1:1) and polymer (2:1) with 
5–10% w/v counter ions (CaCl2). These formulations showed optimum mucoadhesion 
behavior having more than 70% w/v of drug entrapment and particle sizes of 896.70.8 and 
920.61.2 ȝm, respectively58. 
2.2.  Past work done on mucoadhesive gastro retentivedrug delivery system: 
Review of literature: 
Literature review for understanding the study was done by referring the various national and 
international journals, published article in various official standard book and referring 
various websites. 
 Dalvadi et al (2011), developed the mucoadhesive tablets of captopril. The matrix 
tablets of captopril were formulated using different mucoadhesive polymers such as the guar 
gum, xanthan gum, HPMC K4M and K15M in various ratios. Swelling was increased as the 
concentration and viscosity of HPMC increased. Tablets formulated using guar gum and 
xanthan gum alone were eroded faster and dissolved completely within 5-7 hr, while tablet 
containing HPMC remain intact and provided slow release up to 11-12 hr. The formulation 
containing HPMC K15M and xanthan gum (1:1) exhibited maximum bioadhesive adhesive 
strength and in vitro drug release at the end of 24 hr59. 
 
 Sheikh et al (2011), developed the floating-bioadhesive tablets of tramadol. Tablets 
of tramadol were prepared by using varying amounts of carbopol 971P and HPMC, along 
with other excipients. The studies indicated successful formulation of gastroretentive 
compressed matrices with excellent controlled release, mucoadhesion and hydrodynamic 
balance. Good in vitro dissolution profile showing formulation containing carbopol 971 P 
and HPMC (80:125)60.   
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 Chandira et al (2009), developed the mucoadhesive tablets of clarithromycin. Matrix 
tablets of clarithromycin were formulated using different mucoadhesive polymers namely 
carbopol 974 P, HPMC K15M and HPMC K4M and carried out various evaluation parameter 
for tablet. Formulation containing carbopol 974 P and HPMC K4M (1:4) and formulation 
containing carbopol 974 P and HPMC K15M (1.5:3.5) showing cumulative % release were 
93.16 and 96.82 respectively61. 
 
 Arora et al (2011), developed mucoadhesive tablets of domperidone. Oral controlled 
release mucoadhesive matrix tablets have been developed for domperidone as model drug 
using natural mucoadhesive material myrrh oleo gum resin. The tablets were formulated with 
the natural polymer in different concentration (5, 10, 15 and 20 % w/w) employing direct 
compression. All the evaluation parameters were done for tablets including swelling index 
and tensile strength. The tensile strength increase and mucoadhesive strength also increases 
with the increase in natural polymer concentration. This study clearly specifies the potential 
of myrrh oleo gum resin to be used as binder, release retardant and mucoadhesive natural 
material in tablet formulation62. 
 
 Single et al (2010), developed mucoadhesive tablets of ciprofloxacin. The tablets were 
prepared by conventional wet granulation method, using various mucoadhesive hydrophilic 
polymers such as HPMC, sodium CMC, sodium alginate, tragacanth and hydrophobic 
polymer ethyl cellulose have been used for prepared a tablets. Formulation containing HPMC 
and tragacanth has shown better mucoadhesive property63.  
 
 
 Parthiban et al (2010), developed mucoadhesive tablet of cephalexin monohydrate. 
The tablets were prepared by wet granulation method Carbopol 934 P as a primary polymer 
and HPMC K15M, HPMC K4M and HPMC K100M as secondary polymers in different 
proportions has been used to formulate mucoadhesive tablets. All the evaluations were 
carried out for tablets which are essential. Formulation containing combination of carbopol 
934P and HPMC K100M shows 99.51% drug release in 24 hr. The mucoadhesive strength 
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was found to be 95.04 gm. So it has enough strength to adhere on the mucosa for an extended 
period of time64. 
 
 Singh et al (2010), developed mucoadhesive tablets of tramadol HCl by using 
hydrophilic polymer. Tablets were prepared by wet granulation method by using different 
mucoadhesive synthetic and natural polymer such as a guar gum, xanthan gum, HPMC 
K15M and HPMC K100M. The combination of HPMC K15M: HPMC K100M: xanthan 
gum (1:2:1) and HPMC K100M: xanthan gum (2:2) showed greater bioadhesive strength as 
compared to single gum and other hydrophilic polymer combination tablet65. 
 
 Sonar et al (2007), developed bi-layer and floating-bioadhesive tablets of 
rosiglitazone maleate. The sustained layer was compressed and granules of the floating layer 
were added to it then both layers were compressed. HPMC and sodium bicarbonate were 
added to the floating layer and when immersed in 0.1 N HCl. the tablet expands and rises to 
the surface where the drug gradually released without interference for gas bubbles. The in 
vitro drug release from the tablet was controlled by the amount of HPMC in the sustained 
layer. The release of rosiglitazone maleate from the tablets followed the matrix first-order 
release model. The concentration of HPMC significantly affects the drug release rate, 
buoyancy lag-time, detachment force and swelling characteristics of the tablets. The tablet 
was buoyant for up to 8 h the human stomach66. 
 
 Deshmukh et al (2009), developed oral controlled release theophylline anhydrous 
bioadhesive tablets. Tablets were prepared by direct compression method. The combination 
of karaya gum: guar gum (6:4) tablets showed greater bioadhesive strength as compared 
with a single gum and other gum combination tablets. Karaya gum: guar gum loaded tablets 
were not discharged from the mucus membrane and were dissolved in the gastric fluid. An 
increase in the gum concentration increase the drug release profile beyond 12 hr. whereas 
there no significant effect of gum concentration on the bioadhesive strength of the tablets67.   
 
 Senthil et al (2010), developed gastro retentive mucoadhesive tablets of theophylline 
by using natural gums and their combinations. Tablets were prepared by direct compression 
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methods and evaluation parameters were carried out. Different types of natural gums such as 
locust bean gum, carrageenan gum, natural polymer like chitosan, their combination and 
synthetic polymer carbopol were used to formulate the mucoadhesive theophylline tablets. 
Out of which the formulation with the combination of locust bean gum and chitosan (4.5: 3) 
showed greater mucoadhesive strength, good swelling and in vitro drug release than using 
single gum, other gum combinations and synthetic polymer68. 
 
 Yadav et al (2011), developed bilayer and floating-bioadhesive tablets of propranolol 
HCl which exhibiting  a  unique  combination  of  floatation  and  bioadhesion  to  prolong  
residence  in  the  stomach  using  propranolol hydrochloride as a model drug. The sustained 
layer was compressed and granules of the floating layer were  added  to  it  then  both  layers 
were  compressed  using  a  single  station  rotary  press. The in vitro drug release from  the  
tablet was  controlled  by  the  amount  of HPMC  in  the  sustained  release  layer.  The 
floating ability of the tablets was studied. The release of propranolol hydrochloride from the 
tablets followed the matrix first order release model. The  concentration  of  HPMC  
significantly  affects  the  drug  release  rate,  buoyancy  lag-time,  detachment force and 
swelling characteristics of the tablets. The tablet was buoyant for up to 8 hrs. This kind of 
tablet exhibits independent regulation of buoyancy and drug release68. 
 
 Chowdary et al (2003), developed mucoadhesive tablets ofdiltiazem. Tablets 
formulated employing sodium CMC and HPMC alone were slowly eroded and were 
dissolved completely within 4-5 hrs. When ethyl cellulose was incorporated, the tablets 
remained intact and provided slow release of diltiazem for over 10-12 hrs. Tablets formulated 
employing sodium CMC with 5% ethyl cellulose gave slow and complete release over a 
period of 12 hours and were found suitable for the maintenance portion of oral controlled 
release tablets. These tablets exhibited good mucoadhesion in the intestine for 10-12 hrs in 
the x-ray studies. Non-Fickian release was observed from most of the formulations69. 
 
 Dias et al (2009), developed mucoadhesive tablets for acyclovir. Tablets were 
prepared by direct compression and evaluated for mucoadhesive strength and in vitro 
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dissolution parameters. In all the nine formulations studied, the exponent (n) varied between 
0.5266 and 0.7110 showing non-fickian release behavior corresponding to coupled diffusion 
or polymer relaxation, resulting in a controlled and complete drug release up to 12 hrs70. 
 
 Ranga et al (2011) developed gastro retentive floating-bioadhesive tablets of 
glipizide. The tablets are formulated by direct compression method. The prepared tablets 
exhibited satisfactory physical parameter and good in vitro bouncy. The modified in vitro 
assembly was used to measure the bioadhesive strength of tablets with fresh gastric mucosa 
of a goat as a model tissue. Bioadhesion strength was increased with increase concentration 
of carbopol increase. Carbopol 974 P and HPMC K15M combination could be used to design 
effective and stable floating and bioadhesive tablets of glipizide71.   
 
 
 Shinde et al (2010), developed mucoadhesive tablets of niacin using mucoadhesive 
polymer. The tablets were prepared using Sodium Carboxy methyl cellulose (SCMC), 
carbopol940P and HydroxyPropyl Methyl Cellulose (HPMC K4M) as bioadhesive polymers 
to impart mucoadhesion. Formulation containing sodium CMC: carbopol 940P: HPMC K4M 
(1:2.5:1.5) it’s showing good mucoadhesive strength and in vitro release72 
 
 Kumar et al (2010), developed innovative gastro retentive formulation based on 
mucoadhesive patches of pioglitazone. Mucoadhesive films were prepared by using the 
solvent casting technique, allowing a final structure with improved cohesion by 
mucoadhesive swelling and which releases drugs in the stomach. Ethyl cellulose used as rate 
controlling polymer, HPMC and Carbopol-934 were used as mucoadhesive polymers. The 
present work is aimed to formulate and evaluate mucoadhesive films contain Pioglitazone. 
The following physic-chemical studies were film thickness, Surface pH of Films, Percent 
Swelling, folding endurance checked and bioadhesion studies were conducted by using sheep 
stomach and The range was found to be between 57.33 to 80.00 gm/ cm73.  
 
 D. S. Panda, et.al., undertaken a study  to find out the potential of gum from Moringa 
oleifera to act as a binder and release retardant in tablet formulations. The release mechanism 
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was found to be Fickian. The values suggest that the nature of excipient used appeared to 
play a minor role in regulating the release, while the gum content was a major factor75.  
 
 Dhruba Sankar Goswami (2013) et.al., The polymers are playing an important role 
in field of controlled or sustained release drug delivery system. The selected natural 
mucoadhesive agent from gum of Azadirachta indica and Moringa oleifera was successfully 
tested against their adhesive characteristic in the available physical studies like shear stress 
method, wihelmy’s method, falling spheres method along with some synthetic polymer such 
as HPMC and Carbopol 934. The results were comparable to that of same synthetic polymer. 
The mucilage obtained from gum of Azadirachta indica and Moringa oleifera was having 
mucoadhesive character which may replaces the synthetic mucoadhesive polymer76. 
 
 Dhruba Sankar Goswami (2012) et.al., Objective of this research was to design 
mucoadhesive tablets of Amoxicillin trihydrate with moringa gum as a natural mucoadhesive 
polymer. This drug having low biological half-life and the dosing frequency is very high. 
Results for in vitro drug release and wash-off studies suggest that the formulation (F1) 
containing Moringa gum has shown better mucoadhesive property. Other studies have shown 
satisfactory results in all ten formulations. Thus, the present investigation suggests that 
Moringa gum is suitable for preparation of mucoadhesive tablets77. 
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3. DRUG & EXCIPIENTS PROFILE 
 
3.1 Drug profile: 
Gliclazide78, 79, 80 
Structure: 
 
  
 
Empirical formula:C15H21N3O3S 
Chemical name: N-[[(Hexahydrocyclopenta[c] pyrrol-2 (1H)-yl) amine] carbonyl]-4- 
methylbenzesulfonamide. 
Molecular weight: 323.4 
Solubility:Practically insoluble in water, slightly soluble in methanol, sparingly soluble in 
acetone and freely soluble in dichloromethane. 
Appearance:A white or almost white powder. 
Log P: 2.1 
PKa:5.8 
BCS Class:  II -high permeable and less soluble. 
Stability:   Stable under ordinary conditions. 
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Melting point:  179-181 ºC  
Dosing:   The usual initial dose is 40 to 80 mg daily, gradually increased, if necessary, up 
to 320 mg daily. Doses of more than 160 mg daily are given in 2 divided doses. A 
modified-release 
Tablet is also available: the usual initial dose is 30 mg once daily, increased if 
necessary up to a maximum of 120 mg daily. 
Storage:   Itshould be stored at room temperature. 
Pharmacokinetics:  
Gliclazide is readily absorbed from the gastrointestinal tract. It is extensively bound to 
plasma proteins. The half-life is about 10 to 12 hours. Gliclazide is extensively 
metabolized in the liver to metabolites that have no significant hypoglycemic activity. 
Metabolites and a small amount of unchanged drug are excreted in the urine. Oral 
absorption of gliclazide is similar in patients and healthy volunteers, but there is 
intersubjects variation in time to reach peak plasma concentrations *(tmax). Gliclazide has 
low volume of distribution (13 to 24L) in both patients and healthy volunteers due to its 
high protein binding affinity (85 to97%). its plasma clearance is 0.78 L/h (13 ml/min). 
Pharmacodynamics:  
Sulfonylurea causes hypoglycemia by stimulating insulin release from pancreatic ȕ cells. 
Their effects in the treatment of diabetes, however, are more complex. The acute 
administration of sulfonylurea to type 2 DM patients increases insulin release from the 
pancreas. Sulfonylurea also may further increase insulin levels by reducing hepatic 
clearance of the hormone. Sulfonylurea binds to the SUR1 subunits and blocks the ATP-
sensitive K+ channel. The drugs thus resemble physiological secretagogues (e.g., glucose, 
leucine), which also lower the conductance of this channel. Reduced K+ conductance 
causes membrane depolarization and influx of Ca2+ through voltage-sensitive Ca2+ 
channels.  
Adverse drug reaction: 
Hypoglycemia: it is a commonest problem, may occasionally be severe and rarely fatal. It 
is more common in elderly, liver and kidney disease patients and when potentiating drug 
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are added. 
Nonspecific side effects: nausea, vomiting, flatulence, diarrhea or constipation, headache, 
parentheses and weight gain. 
Hypersensitivity: rashes, photosensitivity, purpura, transient’s leucopenia, rarely 
agranulocytosis3. 
 
3.2 Excipient profile 
3.2.1 Chitosan: 
Nonproprietary Names 
BP: Chitosan hydrochloride 
PhEur: Chitosani hydrochloridum 
Synonyms:  
2-Amino-2-deoxy-(1,4)-ß0-D-glucopyranan; deacetylated chitin; deacetylchitin; 
ß0-     1,4-poly Dglucosamine; poly-D-glucosamine; poly-(1,4-ßÅ-D-glucopyranosamine). 
 
Structural Formula: 
 
Chemical name:Poly-b-(1,4)-2-Amino-2-deoxy-D-glucose 
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Molecular weight:10 000–1 000 000 
Category:  
Coating agent; disintegrant; film-forming agent; mucoadhesive; tablet binder; 
viscosity increasing agent. 
Description:   
Chitosan occurs as odorless, white or creamy-white powder orflakes. Fiber 
formation is quite common during precipitationand the chitosan may look like cotton. 
Typical properties: 
Acidity/alkalinity: pH = 4.0–6.0 (1% w/v aqueous solution) 
Density: 1.35–1.40 g/cm3 
Glass transition temperature:2030C  
Moisture content: Chitosan absorbs moisture from the atmosphere.Solubility: 
Sparingly soluble in water; practically insoluble in ethanol (95%), other organic 
solvents, and neutral or alkali solutions at pH above approximately 6.5. Chitosan dissolves 
readily in dilute and concentrated solutions of most organic acids and to some extent in 
mineral inorganic acids  
Viscosity (dynamic): 
A wide range of viscosity types is commercially available. Owing to its high 
molecular weight and linear, unbranched structure, chitosan is an excellent viscosity-
enhancing agent in an acidic environment. It acts as a pseudo-plastic material, exhibiting a 
decrease in viscosity with increasing rates of shear. The viscosity of chitosan solutions 
increases with increasing chitosan concentration, decreasing temperature, and increasing 
degree of deacetylation; 
Stability and Storage Conditions:  
Chitosan powder is a stable material at room temperature,although it is 
hygroscopic after drying. Chitosan should bestored in a tightly closed container in a cool, 
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dry place. ThePhEur 2005 specifies that chitosan should be stored at atemperature of 2–
8oC. 
Applications in Pharmaceutical Formulation or Technology 
 The suitability and performance of chitosan as a component of pharmaceutical 
formulations for drug delivery applications has been investigated in numerous studies. 
These include controlled drug delivery applications, use as a component of mucoadhesive 
dosage forms, rapid release dosage forms, improved peptide delivery, colonic drug 
delivery systems, and use for gene delivery.  
3.2.2. XANTHAN GUM 
Nonproprietary Names 
BP: Xanthan gum 
PhEur: Xanthani gummi 
USPNF: Xanthan gum 
Synonyms: 
Corn sugar gum, Keltrol, Merezan, Polysaccharide B-1459, Rhodigel  
Structure: 
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Empirical Formula:  
It is a high molecular weight polysaccharide gum. It contains D-glucose and D-
mannose as the dominant hexose unit, along with D-glucuronic acid, and is prepared as 
the sodium, potassium, or calcium salt.  
Molecular Weight:    2 x 10
6
 
Description:  
Xanthan gum occurs as a cream or white-colored, odorless, free flowing, fine 
powder 
Functional Category:  
Stabilizing agent, suspending agent, viscosity increasing agent. 
Typical Properties 
Acidity/alkalinity: pH = 6.0–8.0 for a 1% w/v aqueous solution. 
Freezing point: 0oC for a 1% w/v aqueous solution. 
Heat of combustion: 14.6 J/g (3.5 cal/g) 
Melting point: chars at 270oC. 
Solubility:  Practically insoluble in ethanol and ether. Soluble in cold or warm water.  
Viscosity (dynamic): 1200–1600 mPa s (1200–1600 cP) for a 1% w/v aqueous solution at 
25oC. 
Stability and Storage Conditions: 
The bulk material should be stored in a well-closed container in a cool, dry place.  
Incompatibilities: 
Xanthan gum is an anionic material and is not usually compatible with cationic 
surfactants, polymers, and preservatives since precipitation occurs. It is compatible with 
most synthetic and natural viscosity increasing agents.  
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Safety:  
Xanthan gum is widely used in oral and topical pharmaceutical formulations, 
cosmetics and food products and it is generally regarded as nontoxic and nonirritant at the 
levels employed as pharmaceutical excipients. 
Applications in Pharmaceutical Formulation:- 
Xanthan gum is widely used in oral and topical formulations, cosmetics, and foods as a 
suspending and stabilizing agent. It has also been used to prepare sustained release matrix 
tablets.  
Xanthan gum has been incorporated in an ophthalmic liquid dosage form, which interacts 
with mucin, thereby helping in the prolonged retention of the dosage form in the 
precorneal area. 
3.2.3. MICRO CRYSTALLINE CELLULOSE 
Nonproprietary Names: 
BP: Microcrystalline cellulose 
JP: Microcrystalline cellulose 
PhEur: Cellulosum microcristallinum 
USPNF: Microcrystalline cellulose 
Synonyms: 
Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; crystalline cellulose; E460; 
Emcocel; Ethispheres; Fibrocel; Pharmacel; Tabulose; Vivapur. 
Chemical Name and CAS Registry Number: 
Cellulose [9004-34-6] 
Empirical Formula and Molecular Weight: 
(C6H10O5)n ≈36 000 
Wheren ≈ 220. 
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Structural Formula: 
 
 
Functional Category: 
Adsorbent; suspending agent; tablet and capsule diluents; tablet disintegrant. 
Applications in Pharmaceutical Formulation or Technology: 
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluents in oral tablet and capsule formulations where it is used in both wet-
granulation and direct-compression processes. In addition to its use as binder/diluents, 
microcrystalline cellulose also has some lubricant and disintegrant properties that make it 
useful in tableting.  
Uses of microcrystalline cellulose 
Adsorbent 20–90% 
Antiadherent 5–20% 
Capsule binder/diluent 20–90% 
Tablet disintegrant 5–15% 
Tablet binder/diluent 20–90% 
Description: 
Microcrystalline cellulose is purified, partially depolymerized cellulose that occurs as a 
white, odorless, tasteless, crystalline powder composed of porous particles. It is 
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commercially available in different particle sizes and moisture grades that have different 
properties and applications. 
Typical properties: 
Density (bulk): 0.377 g/cm3 
Density (tapped): 0.478 g/cm3 
Density (true): 1.512-1.668 g/cm3 
Melting point: 260-270 0C 
Moisture content: 
Typically less than 5% w/w. However, different grades may contain varying amounts of 
water. Microcrystalline cellulose is hygroscopic. 
 
Stability and Storage Conditions: 
Microcrystalline cellulose is a stable though hygroscopic material. The bulk material 
should be stored in a well-closed container in a cool, dry place. 
Incompatibilities: 
Microcrystalline cellulose is incompatible with strong oxidizing agents. 
 
3.2.4. MORINGA GUM 
SOURCE : Natural gum obtained from the plant Moringa Oleifera. 
PH: Neutral PH 7.0±0.8 
SOLUBILITY: fastly soluble in water at lower concentrations and took more time to 
hydrate on higher concentrations 
CHEMICAL CONSTITUENTS: 
L-Arabinose, D-Galactose, D-glucronic acid, L-Rhamnose,D-Mannose, D-Xylose. 
USES OF MORINGA GUM: 
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Good binder, 
 Retardant, 
  Mucoadhesive polymer,  
  Disintegrant. 
Stability and Storage Conditions: 
Gum should store at lower humidity conditions. Protect from sun light .  
Incompatibilities: 
Natural moringa gum is compatible with al most all compounds. Colour change will be 
seen on longer duration of storage at higher temperatures. 
3.2.5 TALC 
Nonproprietary Names: 
BP: Purified talc 
JP: Talc 
PhEur: Talcum 
USP: Talc 
Synonyms: 
Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium silicate; Luzenac 
Pharma; magnesium hydrogen metasilicate; Magsil Osmanthus; Magsil Star; powdered 
talc;purified French chalk; Pure talc; soapstone; steatite; Superiore. 
Chemical Name: Talc 
Empirical Formula and Molecular Weight: 
Talc is a purified, hydrated, magnesium silicate, approximating to the formula 
Mg6(Si2O5)4(OH)4. It may contain small, variable amounts of aluminum silicate and iron. 
Functional Category:  
Anticaking agent, glidant, tablet and capsule diluents, tablet andcapsule lubricant. 
Typical Properties 
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Acidity/alkalinity: pH = 7–10 for a 20% w/v aqueous dispersion. 
Hardness (Mohs): 1.0–1.5 
Moisture content: Talc absorbs insignificant amounts of water at 2580C and relative 
humidities up to about 90%. 
Particle size distribution: varies with the source and grade of material. Two typical 
grades are 599% through a 74 mm (#200 mesh) or 599% through a 44 mm (#325 meshes). 
Solubility: practically insoluble in dilute acids and alkalis, organic solvents, and water. 
Specific gravity: 2.7–2.8 
Specific surface area: 2.41–2.42m2/g 
Stability and Storage Conditions: 
Talc is a stable material and may be sterilized by heating at 160oC for not less than 1 hour. 
It may also be sterilized by exposure to ethylene oxide or gamma irradiation. Talc should 
be stored in a well-closed container in a cool, dry place. 
Incompatibilities: 
Incompatible with quaternary ammonium compounds. 
Applications in Pharmaceutical Formulation or Technology: 
Talc was once widely used in oral solid dosage formulations as a lubricant and diluents, 
although today it is less commonly used. However, it is widely used as a dissolution 
retardant in the development of controlled-release products. Talc is also used as a 
lubricant in tablet formulations in a novel powder coating for extended-release pellets and 
as an adsorbent.In topical preparations, talc is used as a dusting powder, although it should 
not be used to dust surgical gloves.  
3.2.6. MAGNESIUM STEARATE: 
Nonproprietary Names: 
BP: Magnesium stearate 
JP: Magnesium stearate 
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PhEur: Magnesii stearas 
USPNF: Magnesium stearate 
Synonyms: 
Magnesium octadecanoate; octadecanoic acid, magnesium salt; stearic acid, magnesium 
salt. 
Chemical Name: Octadecanoic acid magnesium salt 
Structure:- 
 
 
   
 
 
 
 
Empirical Formula and Molecular Weight: 
C36H70MgO4      591.34 
Structural Formula: 
[CH3 (CH2)16COO] 2 
Functional Category: Tablet and capsule lubricant. 
Typical Properties 
Crystalline forms: high-purity magnesium stearate has been isolated as a trihydrate, a 
dihydrate, and an anhydrate. 
Density (bulk): 0.159 g/cm3 
Density (tapped): 0.286 g/cm3 
Density (true): 1.092 g/cm3 
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Flash point: 250oC 
Flow ability: poorly flowing, cohesive powder. 
Melting range: 117–1500C (commercial samples); 
126–1300C (high purity magnesium stearate). 
Solubility: practically insoluble in ethanol, ethanol (95%), ether and water; slightly 
soluble in warm benzene and warm ethanol (95%). 
Stability and Storage Conditions:  
Magnesium stearate is stable and should be stored in a well closed container in a cool, dry 
place. 
Incompatibilities: 
Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with strong oxidizing 
materials. Magnesium stearate cannot be used in products containing aspirin, some 
vitamins, and most alkaloidal salts. 
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4. OBJECTIVES 
 
The main objectives of present study are as below- 
1. To carryout preformulation studies for possible drug and polymer interactions by 
infrared studies. 
2. To formulate mucoadhesive tablets by using natural polymers like Chitosan, Xanthan 
gum, and Moringa gum 
3. To develop gastroretentive dosage form for prolong period of time for continuous 
release of drug in the stomach. 
4. Evaluation of prepared mucoadhesive tablets for their physical and chemical 
characteristics. 
5. To carry out Stability studies for optimized formulations as per ICH guidelines. 
6. To maximize bioavailability of the drug and increased patient compliance. 
EXPECTED RESULTS 
1. Tablets prepared should have good satisfactory physico-chemical properties.  
2. Tablet remains for 24 hours in GIT and releases the drug in controlled manner.  
3. Prepared tablets should be stable throughout their shelf-life. 
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5. PLAN OF WORK 
 To carry out literature survey. 
 To carry out selection of suitable drug and polymer. 
 To carry out preformulation studies of the drug and polymer for the characterization. 
 To prepare mucoadhesive gastro retentive tablets by using different available natural 
polymers. 
 To carry out pre-compression parameter of powders. 
 
 To carry out Evaluation of mucoadhesive tablets. 
 
 Physical texture. 
 Thickness. 
 Hardness. 
 Weight variation. 
 % Friability. 
 % Drug content. 
 In vitro drug release study. 
 in vitro mucoadhesive strength. 
 
 swelling study. 
 
 To carry out stability study for optimized formulation. 
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6. MATERIALS & METHODS 
The following materials that were either AR/LR grade or the best possible Pharma grade 
available were used as supplied by the manufacture. 
Table 6.1: List of chemicals with grade and suppliers 
Drug: 
S.No. Drug Grade suppliers 
1. Gliclazide    AR Madras 
Pharmaceuticals 
 
Polymers: 
S.No. Polymers Grade Suppliers 
1. Chitosan LR Yarrow chem 
2. Xanthan gum LR Himedia lab. Pvt.ltd 
3. Moringa Gum - Prepared In Lab. 
 
Other excipients: 
S.No. Materials Grade Suppliers 
1 Micro crystalline cellulose LR yarrowchem 
2 Magnesium stearate  LR Loba Chem. 
3 Talc LR Loba Chem. 
4 Hydrochloric acid LR Loba chem. 
 
Table 6.2: List of instruments used. 
S.NO Equipment Manufacture 
 1 Electronic Balance Contech, Navi Mumbai 
2 Tablet compression machine Shakti  Engeenering ltd. Ahmedabad 
3 UV-Vis spectrophotometer UV-1800, Shimadzu Corporation, Japan 
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4 FTIR spectro photometer Shimadzu 00518, Japan. 
5 Tablet dissolution tester USP 
XXIII 
Electrolab dissolution tester TDT- 08L, 
Mumbai 
6 Friability test apparatus EF-2 Friabilator, Electrolab, Mumbai. 
7 Hot air Oven Servewell Instruments and Equipments 
Pvt. Ltd., Bangalore. 
8 Tap density tester Electrolab ETD-1020, Bombay 
9 Digital melting point apparatus Servewell Instruments and Equipments 
Pvt. Ltd., Bangalore 
10 Hardness tester Monsanto 
11 Digital pH meter Servewell Instruments and Equipments 
Pvt. Ltd., Bangalore 
12 Magnetic stirrer Servewell instrument pvt.ltd 
13 Stability chamber Remi elektrotechnik Ltd, Vasai. 
14 Screw gauze Mitu toyo 
15 Sieves Jayant test sieves, mumbai 
16 Desiccators 
 
Tarsons vacuum desiccator, Kolkata 
 
 
 
6. METHODOLOGY 
6.1 Preformulation studies: 
A comprehensive preformulation study helps in characterizing the physico-chemical 
properties of the drug molecule. It provides the foundation for development of a robust dosage 
form that can sustain the rigors of processing and shelf life. Efforts spent on preformulation 
provide cost savings in the long run, by reducing challenges during formulation development. 
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GOALS OF PREFORMULATION 
1. Too establish the physico chemical parameter of new drug substances 
2. To establish the kinetic rate profile 
3. To establish physical characteristics 
4. To establish compatibility with the common excipients. 
6.1.1. DETERMINATION OF MELTING POINT  
Melting point of drug sample was determined by taking small quantity of drug in a capillary 
tube sealed at one end and was placed in digital melting point apparatus and temperature 
range at which the drug melts was noted. 
6.1.2. Determination of λmax:  
Preparation of 1.2 pH buffer: 
8.5ml of conc. HCl was taken in 1000mL of volumetric flask and final volume was made up 
to 1000mL with distilled water to get 0.1N HCl. 
Most drugs absorbs light UV wavelength (200-400nm), since generally they aromatic contain 
double bond. The solution containing 20µg/mL of gliclazide was prepared and scanned over 
the range of 200-400nm against pH 1.2 buffer as blank using double beam UV 
spectrophotometer. The maximum wave length obtained in the graph was considered as Ȝmax 
for the pure drug. 
 
 
6.1.3. Preparation of calibration curve in 0.1N HCl: 
• Standard solution: 
Accurately weighed 100 mg of gliclazide was dissolved in 10 mL of methanol and the final 
volume was made up to100 mL with 1.2 pH buffer, to get a solution containing 1000 µg/Ml 
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• Stock solution: 
From the standard solution, a stock solution was prepared to give a concentration of 20 µg/mL 
in 1.2 pH buffer. Aliquots of 2, 4, 6, 8 and 10 mL of stock solution were pipette out into 10 
mL volumetric flasks. The volume was made up to the mark with pH 1.2 buffer. These 
dilutions give 4, 8, 12, 16 and 20 µg/mL concentration of gliclazide respectively. The 
absorbance was measured at 229 nm using UV spectrophotometer. 
6.1.4. Compatibility studies of gliclazide and polymers: 
 FTIR studies: 
FTIR spectra help to confirm the identity of drug and to detect the interaction of the drug with 
the carriers. IR spectroscopy of pure drug and physical mixture of drug with polymers was 
carried out using FTIR to check the compatibility between drug and polymers. The IR spectra 
of drug with polymers were compared with the standard IR spectrum of the pure drug. 
Dose calculation for mucoadhesive tablet of gliclazide for 24 hrs81 
Initial dose (D.I) = 30 mg81 
 First order elimination rate constant = KE 
  KE= 0.693/ t1/2 
         = 0.693/10 
                                = 0.0693 
 
 Zero order calculation: 
Desired release rate from maintenance dose= Ko 
  Ko=D.I× KE 
                                =30×0.0693 
        =2.079mg 
 Calculation of maintenance Dose=Dm 
     Dm =Ko× (T- t ½)  
           = 2.079 × (24-10) 
                                   =2.079 × 14 
           =29.10 mg 
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 Corrected Initial dose = C.D.I 
C.D.I =D.I- (Ko ×tmax) 
=30 - (2.079×10) 
           =30 - 20.27 
            =09.21mg 
 Total dose =Dm+ C.D.I 
            =29.10+09.21 
            =38.31mg 
For ease in calculation, it is rounded off as 40 mg 
 
 
 
6.2. Method of formulation  
In the present investigation, an accurately weighed quantity of Gliclazide and the 
subjected polymers, remaining excipients were added together in mortar& pestle and 
triturated. Tablets were prepared by Direct Compression Method. 
 
Table 6.3: Preliminary Formulation 
Ingredients PF1 PF2 PF3 
GLZ 40 40 40 
Chitosan 100 - - 
Xanthan gum - 100 - 
Moringa gum - - 100 
MCC 50 50 50 
Magnesium  stearate 5 5 5 
Talc 5 5 5 
Total (mg) 200 200 200 
 
                *All quantities in mg/tablet 
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 Screening of polymers and excipients: 
Preliminary formulations were designed by different natural polymer for screening of 
mucoadhesive system. Based on the results obtained, further experiments were designed using 
various natural polymers to develop optimized formula. 
 
Table 6.4:  formulation of mucoadhesive tablets of gliclazide 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
GLZ 40 40 40 40 40 40 40 40 40 40 
Chitosan 30 - 40 - 50 - 60 - 30 40 
Xanthan gum 
- 30 - 40 - 50 - 60 40 30 
Moringa gum 70 70 60 60 50 50 40 40 30 30 
          MCC 70 70 60 60 50 50 40 40 30 30 
Magnesium  
stearate  
5 5 5 5 5 5 5 5 5 5 
Talc 5 5 5 5 5 5 5 5 5 5 
Total (mg) 200 200 200 200 200 200 200 200 200 200 
               *All quantities in mg/tablet 
6.3. Evaluation parameters: 
6.3.1 Precompressional parameters82:  
1) Bulk density 
2) Tapped density 
3) Angle of repose 
4) Hasusner’s ratio 
5) Carr’s consolidation index 
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1) Bulk density: 
It is the ratio of total mass of powder to the bulk volume of powder. Accurately 
weighed batch (F1 –F10) powder was placed in 10 mL graduated measuring cylinder. Initial 
volume was observed. The Dbandwas calculated in gm/ mL using following formulae, 
Db = M/Vb………………… (1) 
                                           Where, Db = Bulk density 
                                                        M = Mass of the powder 
Vb = Bulk volume of powder 
2) Tapped density: 
Accurately weighed batch (F1 –F10) powder was placed in 10 mL graduated 
measuring cylinder.The cylinder was tapped initially 100 times from a distance of 14 + 2 mm. 
The tapped volume was measured to the nearest graduated unit. Again the tap volume was 
measured to the nearest graduated unit. The Dtwere calculated in g/ mL using following 
formulae, 
Dt = M/Vt ………………….. (2) 
           Where, Dt = Tapped density 
                       Vt = Tapped volume of the powder 
                       Dt = Tapped density 
                                    M = mass of the powder 
3) Angle of repose: 
Good flow properties are critical for the development of any pharmaceutical tablets, 
capsule or powder formulations. Angle of repose is defined as the maximum angle possible 
between the surface of the pie of powder and horizontal plane. It is performed to determine 
the flow property of powder done by the funnel method. The powder mass was allowed to 
flow through the funnel orifice, kept vertically to a plane paper kept on horizontal surface, 
giving a heap angle of powder on a paper. The diameter of the powder cone was measured and 
angle of repose was calculated using the following equation  
tanθ = h/r ………………………………..(3) 
Where, h and r are the height and radius of the powder cone, respectively. Flow 
properties for different values of angle of repose were given below 
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              Table 6.5: Comparison between Angle of Repose and Flow Property  
Angle of Repose Flow 
< 25 Excellent 
25 – 30 Good 
30 – 40 Moderate (addition of 0.2% 
glidant required) 
> 40 Poor 
 
 
4) Hasusner’s ratio: 
Hasusner’s ratio carried out by tapped density divided bulk density. Hasusner′s ratio = 𝑇ܽ𝑝𝑝݁݀ ݀݁𝑛ݏ𝑖ݐ𝑦𝐵ݑ݈݇ ݀݁𝑛ݏ𝑖ݐ𝑦  
Table no 6.6 Hausner’s ratio 
Hausner’s ratio Types of Flow 
Less than 1.25 Good flow 
1.25- 1.5 Moderate 
More than 1.5 Poor flow 
 
5) Carr’s consolidation index: 
Carr developed an indirect method of measuring powder flow from bulk densities. 
The % compressibility of the powder was direct measure of the potential powder arch or 
bridge strength and stability. Carr’s index of each formulation was calculated using the 
given formula. 
Carr’s index (%) = [(Dt –Db) x 100]/Dt …………………….. (4) 
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Table 6.7: flow property related to Carr’s index. 
CARR’S  INDEX TYPE OF FLOW 
5-15 Excellent 
12-16 Good 
18-21 Fair to passable 
23-35 Poor 
33-38 Very poor 
>40 Extremely poor 
 
6.3.2. Post compression parameters83: 
1) Appearance: 
The tablets were checked for presence of cracks, pinholes etc. There should be uniformity in 
the color and the dimensions of the tablets. 
2) Hardness: 
This test is used to check the hardness of the tablet, which may undergo chipping or breakage 
during storage, transportation, and handling. In this, three tablets were selected randomly and 
the hardness of each tablet was measured with Monsanto hardness tester. The hardness is 
usually measured in terms of kg/cm2.  
3) Thickness: 
Thickness of tablet was important for uniformity of the tablet size. In this three tablets were 
selected randomly and the hardness of each tablet was measured with using screw gauze. 
 
4) Friability test: 
          Friability test was carried out to evaluate the hardness and stability instantly. In roche 
friabilator, 10 tablets were weighed (W0) initially and put in a tumbling and rotating apparatus 
drum. Then they were subjected for completion of 4 min or 100 rpm, the tablets were again 
weighed. The % loss in weight or friability (F) was calculated by the formula given below. 
 % ݂ݎ𝑖ܾܽ𝑖݈𝑖ݐ𝑦 = ௪௘𝑖𝑔ℎ௧𝑖𝑛𝑖𝑡𝑖𝑎𝑙− ௪௘𝑖𝑔ℎ௧𝑓𝑖𝑛𝑎𝑙௪௘𝑖𝑔ℎ௧𝑖𝑛𝑖𝑡𝑖𝑎𝑙  × ͳͲͲ………………..(5) 
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5) Weight variation:
 
          This test was performed to maintain the uniformity of weight of each tablet, which 
should be in the prescribed range. This was done by weighing 10 tablets at random and 
average weight was calculated. Not more than two of individual weight deviates from the 
average weight. The weight data from the tablets were analyzed for sample mean and percent 
deviation. 𝑃𝐷 = 𝑊𝑎௩𝑔   − 𝑊𝑖𝑛ௗ𝑊𝑎௩𝑔  × ͳͲͲ 
Where, PD = percentage deviation 
                     Wavg = average weight of tablets 
                          Wind = individual weight of tablets 
Table 4.8: percentage deviation allowed under weight variation test 
Average weight of tablets Percentage deviation 
130 or less 
 
130-324 
 
More than 324 
10 
 
7.5 
 
5 
 
6) Uniformity of drug content84: 
The content uniformity was mandatory for tablets. This test was performed by taking 
five tablets were selected randomly, weighed and powdered. A tablet triturate equivalent to 40 
mg of drug weighed accurately, dissolved in 10 mL methanol then final volume made up to 
100 mL by using pH 1.2 buffer. Further dilutions were done suitably and absorbance was 
measured at 229nm using UV spectrophotometer. 
 
7) Swelling index85: 
The swelling of tablet involves the absorption of a liquid resulting in an increase in weight 
and volume. Liquid uptake by the particle results to saturation of capillary spaces within the 
particles. The liquid enters the particles through pores and bind to large molecule breaking the 
hydrogen bond and resolution in the swelling of particle. One tablet from each batch was 
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weighed and placed in a Petri plate containing 25 mL of pH 1.2 buffer solution. After each 2 
hrs interval the tablet was removed from plate, removes excess of buffer by using filter paper 
and weighed again up to 24 hrs. The swelling index was calculated using following formula. 𝐒ܟ܍𝐥𝐥𝐢ܖ𝐠 𝐢ܖ܌܍ܠ ሺ𝐒. 𝐈ሻ = 𝐖𝐭   − 𝐖ܗ𝐖ܗ  × ૚૙૙ 
Where, Wt = Weight of tablet at time t 
Wo = Weight of tablet before placing in the Petri plate. 
 
8) In vitrodissolution studies85: 
Dissolution tests were performed in USP dissolution eight dissolution apparatus II (paddles) 
at 37±0.5°C. The baskets were rotated at a speed of50 rpm. The test was performed in 
37±0.5°C with a rotation speed of 50 rpm using 900 mL of 0.1 N HCl, pH 1.2, as a dissolution 
medium. According to the sampling plan, samples of 5 mL were withdrawn till 24 hrs and 
immediately replaced with an equal volume of the respective dissolution medium maintained 
at 37±0.5°C. Test samples were filtered through Whatman filter paper for Gliclazide at 229 
nm using a blank solution as reference with a UV-VIS double-beam spectrophotometer 
9) Release kinetics: 
The results of in vitro release profiles obtained for all the HBS formulations were fitted 
into four models of data treatment as follows:  
1. Cumulative percent drug released versus time (zero-order kinetic model).  
           2. Log cumulative percent drug remaining versus time. (First-order kinetic model).  
3. Cumulative percent drug released versus square root of time. (Higuchi’s model).  
4. Log cumulative percent drug released versus log time (Korsmeyer-Peppas equation).  
 
 
 
1) Zero Order Kinetics: A zero-order release would be predicted by the following 
equation.  
A
t 
= A
0 
– K
0
t……………………………………. (6) 
                Where, 
A
t 
= Drug release at time‘t’  
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A
0 
= Initial drug concentration  
K
0 
= Zero-order rate constant (hr
-1
).  
When the data is plotted as cumulative percent drug release versus time, if the plot is 
linear then the data obeys zero-order release kinetics, with a slope equal to K
0
86
. 
 
 
2.First Order Kinetics: A first-order release would be predicted by the following equation  
Log C = Log C
0 
– 303.2Kt………………………..(7) 
                     Where, 
C = Amount of drug remained at time‘t’ 
C
0 
= Initial amount of drug  
K = First-order rate constant (hr.
-1
). 
When the data is plotted as log cumulative percent drug remaining versus time, yields a 
straight line, indicating that the release follows First-order kinetics. The constant ‘K’ can be 
obtained by multiplying 2.303 with slope values86. 
 
3. Higuchi’s Model:  
Drug released from the matrix devices by diffusion has been described by following 
Higuchi’s classical diffusion equation.  
 Q = ୈ∈ሺ 2 A−∈େsሻ𝐶௦௧τ ½  ……………….. (8) 
Where,  
Q = Amount of drug released at time‘t’  
D = Diffusion coefficient of the drug in the matrix  
A = Total amount of drug in unit volume of matrix  
C
S 
= The solubility of the drug in the diffusion medium  
ε = Porosity of the matrix  
τ = Tortuosity  
t = Time (hrs) at which ‘Q’ amount of drug is released.  
Equation-8 may be simplified if one assumes that D, C
S 
and A are constant. 
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 Then equation-8 becomes: 
Q = Kt
½………………………….. (9)
 
When the data is plotted according to equation-4 i.e., cumulative drug released versus 
square root of time, yields a straight line, indicating that the drug was released by diffusion 
mechanism87.The slope is equal to ‘K’. 
 
4. Korsmeyer and Peppas Model:  
The release rates from controlled release polymeric matrices can be described by the equation 
(10) proposed by korsmeyer et al
88
.  
 
Q = K
1
t
n………………………………. (10) 
Q is the percentage of drug released at time‘t’, K is a kinetic constant incorporating 
structural and geometric characteristics of the tablets and ‘n’ is the diffusional exponent indicative 
of the release mechanism. 
For Fickian release, n=0.45 while for anomalous (Non-Fickian) transport, n ranges 
between 0.45 and 0.89 and for zero order release, n = 0.89 
 
10) In vitro mucoadhesive strength85: 
Mucoadhesion strength of the tablet was measured by using sheep stomach mucosa as 
model mucosal membrane. Fresh sheep stomach mucosa was obtained from a local slaughter 
house and was used within 2-3 h of slaughtering. The mucosal membrane was washed with 
distilled water and then with pH 1.2. 
 
The mucoadhesive strength measurement apparatus was fabricated locally as shown in 
to the Figure no 4.1. The mucoadhesive strength of the tablets was determined using this 
locally fabricated apparatus.  The weight at which the tablet was detached was recorded. The 
mean value of three trials was taken for each set of formulations. After each measurement, the 
tissue was gently and thoroughly washed with phosphate buffer and left for 5 minutes before 
placing a new tablet to get appropriate results for the formulation. 
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11) Stability studies: 
Stability of a dosage form has been defined as the ability of a particular formulation, in a 
specific container, to remain within its physical, chemical, therapeutic and toxicological 
specification. 
The purpose of stability studies is to provide evidence that the quality of drug substance 
or drug product varies with time under the influence of a verity of environmental factors such 
as temperature, humidity and light enables recommended storage conditions, re-testing 
periods and shelf-lives to be established. 
Accelerated stability study was carried out as per the ICH guidelines. 
Selected formulations were subjected to determine its shelf life i.e. stability study by 
using accelerated stability chamber, according to the WHO guidelines. The tablets were stored 
in the stability chamber under temperature 40 ± 20C and 75 ± 5 % RH (relative humidity) for 
90 days. After the specified period the tablets are subjected to physical appearance, drug 
content and dissolution study. 
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 7. RESULTS AND DISCUSSION 
 
7.1. PREFORMULATION STUDIES 
7.1.1. Melting point determination 
Melting point of Gliclazide was obtained in the range of 177-179 0C.  
The standard melting point value of gliclazide is 179 0C. 
7.1.2. Drug-polymer interaction studies by FT-IR 
Fourier-transform infrared (FT-IR) spectra were obtained by using an FT-IR 
Spectrometer-SHIMADZU. The Dug sample gliclazide alone and with the subjected 
polymers were previously ground and mixed thoroughly with potassium bromide, an infrared 
transparent matrix, at 1:5 (Sample: KBr) ratio, respectively. The KBr discs were prepared by 
compressing the powders at a pressure of 5 tons for 2 min in a hydraulic press. 
 
Table No. 7.1. IR SPECTRUM OF GLICLAZIDE 
Groups Peaks (cm-1) 
N-H (amine group) 3413.15 
C=O stretching 1709.15 
C=C aromatic ring 1473 
C-H 1432 
O=S=O (sulphoxide group) 1164.08 
C-H stretching 1086.92 
C-S stretching 6668.36 
 
7.1.3. Drug - polymer compatibility studies: 
              Under the pre formulation studies the drug was studied for the Compatibility studies. 
Pure drug gliclazide with selected polymers were carried out prior to the formulation of 
tablets. IR spectra of pure drug and polymers were taken. All the characteristic peaks of 
gliclazide were present in spectra at respective wavelengths. Thus, indicating compatibility 
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between drug and polymers. It shows that there was no significant change in the chemical 
integrity of the drug.  The FT IR spectrum of the drug and polymers were recorded in figure 
no.7.1, 7.2, and 7.3. 
 
7.1.4.Standard Plot of Gliclazide 
The Ȝmax of gliclazide was determined in pH 1.2 buffer which was scanned between 
200 – 400 nm in the UV spectrophotometer. It was found to be 229 nm.The absorbance 
reading of gliclazide standard solution containing 2-20 µg/mL (Beers range) of drug in pH 
1.2 buffers at the maximum wavelength of 229 nm.  The calibration curve for Gliclazide with 
slope, intercept, regression coefficient and molar absorptivity were determined. The 
calculations of drug content and in vitro drug release study are based on this standard 
calibration curve.  
Fig.no. 7.4. Scanning Of Gliclazide 
 
 
 
 
 
 
Table no. 7.2: Calibration data of gliclazide in pH 1.2 buffer 
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S.No Concentration 
(µg/ml) 
Avg. absorbance 
at 229 nm 
Standard 
deviation(SD) 
Molar absorptivity 
L/mol.cm 
1 4 0.189 0.021 15280 
2 8 0.354 0.191 14755 
3 12 0.542 0.006 14606 
4 16 0.709 0.011 14573 
5 20 0.901 0.017 14569 
 
Figure no 7.5: Calibration curve of Gliclazide in pH 1.2 
buffer 
 
 
7.2. Evaluation of powder properties 
7.2.1. Bulk density and Tapped density:           
The loose bulk density (LBD) and Tapped bulk density (TBD) of the powders of different 
formulations were evaluated before the compression of powders in to tablets.  The bulk 
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density and the tapped density for all the formulations varied from 0.4284±0.005 to 
0.4679±0.003 gm/cm3 and 0.4763±0.011 to 0.5361±0.0105gm/cm3 respectively. 
 
             The values obtained lies within the acceptable range. The difference exists between 
the bulk density and tapped density found to be very few. This result helps in calculating the 
% compressibility of the powder. 
Table No.7.3.bulk density and tapped density of the powder formulation 
 
7.2.2. Angle of repose (θ): 
The angle of repose data for all the formulations ranges from 180.92’±0.313 to 
250.37’±0.171.The data were tabulated in the table no 7.4.Angle of repose of all the 
formulations were found to be less than 30o, which indicates a good flow property of the 
powders. 
S.No of Formulation Bulk Density Tapped Density 
PF1 0.4432±0.049 0.5124±0.006 
PF2 0.4431±0.049 0.5124±0.006 
PF3 0.4679±0.003 0.5361±0.005 
F1 0.4477±0.005 0.5357±0.008 
F2 0.4580±0.006 0.5357±0.008 
F3 0.4284±0.005 0.4918±0.007 
F4 0.4511±0.005 0.5218±0.077 
F5 0.4313±0.005 0.4839±0.006 
F6 0.4285±0.005 0.4979±0.006 
F7 0.4651±0.006 0.5313±0.007 
F8 0.4285±0.005 0.4763±0.011 
F9 0.4361±0.005 0.4840±0.013 
F10 0.4477±0.005 0.5173±0.007 
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Table No.7.4. Angle Repose of the Powder Formulation 
 
 
 
 
 
 
 
 
 
 
 
7.2.3. Hausner’s ratio:  
The result of Hausner’s ratio of all formulations ranges from 1.1098±0.027to 
1.1965±0.017. Results of Hausner’s ratio of all formulations were shown in Table no 7.5 
which indicates that the flow ability of all the formulation. 
 
 
 
 
 
 
S.NO  OFFORMULATION ANGLE OFREPOSE  (θ) 
PF1 190.98’±0.335 
PF2 180.92’±0.313 
PF3 250.37’±0.171 
F1 24˚.47±0.013 
F2 23˚.98±0.149 
F3 22˚.83±0.396 
F4 22˚.53±0.334 
F5 210.69±0.439 
F6 210.31±0.234 
F7 200.43±0.135 
F8 20˚.93±0.313 
F9 20˚.13±0.191 
F10 19˚.89±0.147 
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Table No.7.5. Hausner’s Ratio of the Powder Formulation 
 
 
7.2.4. Carr’s consolidation index: 
The results of the Carr’s consolidation index of all the formulations ranges from 
09.80 % to 16.42 %. Results of Carr’s consolidation index of all the formulations were 
shown in the Table no 7.6. Results clearly showed that the flow ability of all the formulations 
was good and also the powder had good compressibility. 
 
 
S.NO  OF FORMULATION HAUSNER’S RATIO 
PF1 1.1561±0.003 
PF2 1.1956±0.002 
PF3 1.145±0.003 
F1 1.1965±0.017 
F2 1.1696±0.016 
F3 1.1479±0.002 
F4 1.1567±0.002 
F5 1.1219±0.025 
F6 1.1619±0.017 
F7 1.1423±0.032 
F8 1.1115±0.030 
F9 1.1098±0.027 
F10 1.1554±0.002 
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Table No.7.6. Carr’s Consolidation Index of the Powder Formulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.3. Post compression parameters: 
The formulated tablets were subjected for post- compressional evaluation such as 
1. Shape of tablets. 
2. Friability. 
3. Hardness. 
4. Weight variation. 
5. Thickness. 
6. Uniformity of drug content. 
7. In vitro dissolution. 
8. In vitro mucoadhesive strength. 
9. In vitro swelling study 
10. Stability Studies 
 
S.NO OF FORMULATION CARR’S CONSOLIDATION INDEX 
PF1 15.39 
PF2 15.41 
PF3 14.95 
F1 16.42 
F2 14.50 
F3 12.89 
F4 13.54 
F5 10.87 
F6 13.93 
F7 12.46 
F8 10.03 
F9 09.80 
F10 13.45 
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7.3.1. Shape of the tablets: 
Visually inspection of prepared all tablets were done. The shapes of the tablets were 
found to be good. 
 
7.3.2. Friability (F)  
Friability determines the strength of the tablets. The values of friability test were 
given in the Table no 7.7. The friability for all the formulations was below 1% indicating 
that the friability was within the prescribed limits. The results of friability test indicates that 
the tablet possesses good mechanical strength. The friability value ranges from 0.67 to 0.92 
7.3.3. Hardness:  
The mean hardness values were measured for all the formulation using Monsanto 
hardness tester. The results were tabulated in Table no 7.7. The hardness value ranges from 
4.97± 0.032 to 6.93± 0.133 kg/cm2.      
7.3.4. Weight variation: 
Twenty tablets were randomly selected from each formulation and evaluated. The 
average weight of each formulation was recorded and is shown in Table no 7.7. The 
obtained data were almost uniform. The values of tablets ranging from 197.9± 1.786 to 
199.8± 1.259 mg. All the tablets passed weight variation test as the % weight variation was 
within the Pharmacopoeia’s limits of ±7.5% of the weight.     
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Table no 7.7: Postcompressional parameters of gum formulations 
7.3.5. Thickness  
The thickness of the tablets was reported in the micrometer (mm).The thickness of 
tablet indicates that, die fill was uniform. The thickness depends on the size of the punches 
(8 mm) and the weight of one tablet (200 mg). The average weight of each formulation was 
recorded in shown in Table no 7.8. The value of thickness ranges between 2.839± 0.026 to 
3.129± 0.043 mm.  
7.3.6. Uniformity of drug content 
The % drug content of all the formulated tablets were found within the limit. % drug 
content value of gliclazide was within 94.89± 0.886% to 97.89± 1.009%.The results within 
the range indicate uniform of mixing. The Table no 7.8 shows the % drug content in each 
formulation. 
Formulation Code  Friability (%) Hardness  
(kg/cm2 )   
 
Weight Variation(mg) 
(n=20) 
PF1 0.83 5.04± 0.051 198.4± 1.471 
PF2 0.74 4.97± 0.032 198.7± 1.364 
PF3 0.79 6.93± 0.133 199.4± 1.658 
F1 0.88 6.42± 0.0421 199.5± 1.865 
F2 0.83 6.23± 0.121 198.6± 1.371 
F3 0.87 6.29± 0.121 198.9± 1.452 
F4 0.77 5.99± 0.111 199± 2.258 
F5 0.88 5.85± 0.113 198.9± 1.492 
F6 0.68 5.54± 0.119 198.7± 1.531 
F7 0.87 5.35± 0.046 197.9± 1.786 
F8 0.92 5.23± 0.075 199.3± 1.942 
F9 0.67 5.14± 0.924 198.6± 1.545 
F10 0.73 5.03± 0.0421 199.8± 1.259 
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Table no 7.8: Postcompressional parameters of gum formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.3.7Swelling study 
Swelling index was carried out for preliminary formulation and results were shown 
in Table no. 7.9 .The swelling index of the tablets from each formulation (F1 to F10) was 
evaluated and the results are mentioned in Table no 7.10 
 PF1 to PF3 were hydrated to an extent of 220.44±0.512, 312.59±0.514, 
165.44±0.847,  
 F1 to F5 were hydrated to an extent of 118.05, 157.31, 102.83, 132.21, and 98.28. 
 F6 to F10 were hydrated to an extent of121.78, 101.91, 121.48, and 255.98. 
 
 
 
Formulation Code Thickness (mm) (n=3) 
Mean±S.D 
 
Drug Content (%) (n=3) 
Mean±S.D 
PF1 2.899± 0.083 94.89± 0.886 
PF2 2.879± 0.046 97.78± 0.572 
PF3 3.059± 0.019 96.73± 1.001 
F1 2.969± 0.038 97.98± 1.154 
F2 2.839± 0.026 96.27± 0.891 
F3 2.929± 0.021 97.59± 0.672 
F4 3.049± 0.039 97.40± 0.866 
F5 2.969± 0.054 97.59± 0.865 
F6 3.129± 0.043 96.82± 0.861 
F7 2.919± 0.021 96.43± 0.869 
F8 2.959± 0.047 96.24± 0.586 
F9 2.999± 0.079 97.83 ± 0.654 
F10 3.019± 0.033 97.89± 1.009 
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 Table no 7.9:  % swelling index for preliminary formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FORMUL. 
CODE 
% Swelling index     Time (hrs)    (n=3)      Mean±S.D 
2 Hrs 4 Hrs 6 Hrs 8 Hrs 10 
Hrs 
12 
Hrs 
16 
Hrs 
20 
Hrs 
24 
Hrs 
PF1 94.48 
±0.741 
136.44 
±0.235 
156.74 
±0.824 
166.84 
±0.941 
176.64 
±0.236 
185.94 
±0.613 
192.74 
±0.312 
208.14 
±0.841 
220.44 
±0.512 
PF2 211.17 
±0.212 
269.57 
±0.906 
279.47 
±0.548 
285.37 
±0.726 
295.37 
±0.749 
297.77 
±0.514 
305.67 
±0.701 
308.87 
±0.847 
312.59 
±0.514 
PF3 69.34 
±0.514 
80.56 
±0.424 
93.44 
±0.814 
105.52 
±0.716 
117.45 
±0.476 
129.68 
±0.164 
141.55 
±0.258 
153.65 
±0.371 
165.44 
±0.847 
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Table no 7.10:  % swelling index for polymer gum formulations 
 
 
7.3.8. In vitro dissolution  
In vitro drug release studies were performed by using USP XXIII dissolution test apparatus-
II at 50rpm using 900 mL of 1.2 pH buffer maintained at 37±0.5ºC as the dissolution 
medium. 
7.3.8.1. In vitro dissolution studies of preliminary & polymer formulations: 
The in vitro drug release profiles for the preliminary formulations) were tabulated in Table 
no 7.11. The plot of cumulative percentage drug release V/s time (Hr) for preliminary 
formulations were plotted and depicted in Figure. 
 
FORM. 
CODE 
 
% Swelling index     Time (hrs)    
2 Hrs 4 Hrs 6 Hrs 8 Hrs 10 Hrs 12 Hrs 16 Hrs 20 Hrs 24 Hrs 
F1 41.15 50.7625 60.375 69.9875 79.6 89.2125 98.825 108.4375 118.05 
F2 90.75 99.07 107.39 115.71 124.03 132.35 140.67 148.99 157.31 
F3 34.98 43.46125 51.9425 60.42375 68.905 77.38625 85.8675 94.34875 102.83 
F4 72.17 79.675 87.18 94.685 102.19 109.695 117.2 124.705 132.21 
F5 32.61 40.81875 49.0275 57.23625 65.445 73.65375 81.8625 90.07125 98.28 
F6 62.36 69.7875 77.215 84.6425 92.07 99.4975 106.925 114.3525 121.78 
F7 32.94 41.56125 50.1825 58.80375 67.425 76.04625 84.6675 93.28875 101.91 
F8 57.73 65.69875 73.6675 81.63625 89.605 97.57375 105.5425 113.5113 121.48 
F9 114.97 132.5963 150.2225 167.8488 185.475 203.1013 220.7275 238.3538 255.98 
F10 127.38 144.6788 161.9775 179.2763 196.575 213.8738 231.1725 248.4713 265.77 
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Table no 7.11:  % Cumulative drug release of Preliminary formulations 
 
 
 
 
 
 
 
Time 
(Hrs) 
PF1 PF2 PF3 
1 8.506   ± 1.084 9.895 ±1.377 6.631 ± 1.310 
2 14.804 ± 1.316 18.631  ±1.681 13.467 ± 1.090 
3 24.908 ± 1.317 25.797 ± 1.093 20.755 ± 1.316 
4 32.429 ± 0.908 29.656 ± 1.680 29.123 ± 1.090 
5 40.630 ± 0.800 33.150 ± 0.306 35.502 ± 1.090 
6 47.967 ± 1.833 38.724 ± 0.522 41.708 ± 1.047 
7 55.994 ± 0.911 42.228 ± 0.797 49.170 ± 0.907 
8 65.066 ± 1.833 45.893 ± 0.304 56.124 ± 1.566 
9 76.054 ± 1.202 50.253 ± 0.522 67.950 ± 0.909 
10 84.969 ± 1.209 53.750  ± 0.601 74.717 ± 1.382 
12 88.316 ± 1.589 60.192 ± 0.523 81.700 ± 1.979 
16 - 71.166 ± 0.904 87.0694±1.516 
20 - 79.039 ± 1.801 89.148±1.719 
24 - 87.589 ± 1.670 - 
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Table no 7.12:  % Cumulative drug release of polymer gum Formulations (F1-F5) 
 
 
 
Time 
(Hrs) 
F1 F2 F3 F4 F5 
1 
18.923±1.591 14.583±0.520 16.840±1.310 13.888±1.310 10.651± 1.172 
2 
21.806±0.299 19.872±1.565 20.753±1.588 25.424±1.681 20.190±0.306 
3 
25.120±1.378 23.721±0.608 24.073±0.910 29.481±1.600 22.363±0.522 
4 
28.611±1.091 26.867±  1.087 26.695±1.379 36.100±1.386 26.789± 0.302 
5 
31.408±0.907 29.662±1.208 29.835±1.385 42.039±1.598 34.817±0.527 
6 
34.722±0.800 32.455±1.384 33.151±1.598 50.406±1.598 37.158±0.521 
7 
38.212±0.906 35.042±1.511 35.773±1.600 55.139±1.315 42.682±1.565 
8 
41.357±0.907 38.042±1.682 38.392±1.093 66.624±0.802 43.659±0.804 
9 
44.673±0.800 41.529±1.512 41.531±1.316 75.368±1.566 45.974±1.283 
10 
47.295±1.206 45.021±1.386 44.500±0.528 81.493±1.837 48.912±1.191 
12 
54.775±1.316 50.943±1.091 49.898±1.594 87.082±0.801 56.778±0.801 
16 
66.275±1.088 64.691±0.603 62.428±0.788 - 65.226±1.594 
20 
78.665±1.679 82.996±1.313 74.130±1.313 - 79.369±1.836 
24 
82.379±1.683 87.264±1.318 84.090±0.802 - 87.020±1.317 
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Table no 7.13:  % Cumulative drug release of polymer gum Formulations (F6-F 
 
7.3.7. Release kinetic data 
In order to describe the kinetics of the release process of drug in all formulations, 
various equations were used, such as zero-order rate equation, which describe the system 
where release rate was independent of the concentration of the dissolved species. 
The first-order equation describes the release from the systems where dissolution rate 
was dependent on the concentration of the dissolved species. 
Time 
(Hrs) 
F6 F7 F8 F9 F10 
1 
9.722± 1.084 16.145± 1.877 17.708± 1.041 10.243±0.795 11.631±0.795 
2 
18.109±0.304 23.527±0.510 22.841± 0.305 19.154±0.800 20.377±1.381 
3 
20.933±0.520 28.081±0.798 24.952± 1.379 21.981±0.902 24.071±0.528 
4 
24.768± 0.300 30.016±0.304 29.304± 0.542 24.774±0.305 26.174±1.563 
5 
29.824±0.520 34.888±0.796 32.627± 1.086 29.303±0.520 30.005±1.599 
6 
32.977±0.523 38.213±0.525 35.249± 0.800 32.627±0.796 34.540±0.908 
7 
37.682±1.565 43.266±0.798 39.430± 0.799 36.812±1.595 39.253±1.382 
8 
40.659±0.804 45.898±0.800 42.579± 0.799 40.828±0.908 42.751±0.608 
9 
43.974±1.382 50.253±0.525 45.895± 0.605 44.149±1.087 46.590±0.523 
10 
47.812±1.091 54.444±0.523 49.906± 0.798 47.987±0.605 50.431±0.798 
12 
54.778±0.801 61.932±1.086 56.525± 0.905 57.383±0.798 59.827±0.299 
16 
65.226±1.594 72.738±1.047 72.013±11.315 79.310±0.299 80.886±0.301 
20 
83.369±1.837 82.346±0.300 87.203± 0.294 90.36±1.085 91.072±0.902 
24 
89.002±1.387 89.691±1.085 91.107± 0.502 94.24±1.037 94.07±0.790 
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Higuchi square root equation describes the release from system where solid drug was 
dispersed in insoluble matrix, and the rate of drug release is related to the rate of diffusion. 
The Korsmeyer-peppas equation was used to analyze the release of pharmaceutical 
polymeric dosage forms, when the release mechanism is not well known or when more than 
one type of release phenomenon could be involved.  
The value of n gives an indication of the release mechanism, When n = 1, the release 
rate is independent of time (Zero order), n = 0.5 for Fickian diffusion and when between 0.5 
and 1.0, diffusion and non-Fickian transport or anomalous diffusion are implicated. Lastly 
when n is more than 1.0 supercase II transport is apparent. 
7.3.9.1.Release kinetic data for preliminary formulation: 
Release kinetic data for preliminary formulations tabulated in Table no 7.14 and   zero-order 
plot (Figure no 7.3), first-order plot (Figure no 7.4),Higuchi plot (Figure no 7.5) and  
Korsmeyer–Peppas plot (Figure no 7.6). 
                    Table no 7.14: Release kinetics data of preliminary formulations 
 
Formln. 
code 
Mathematical models (kinetics) 
Zero order 
(R) 
First order 
(R) 
Higuchi 
(R) 
Korsmeyer-Peppas 
n (R) 
PF1 0.9867 0.9412 0.9741 0.993 0.9957 
PF2 0.9597 0.9903 0.9988 0.665 0.9812 
PF3 0.8825 0.9566 0.9543 0.928 0.9724 
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Figure no. 7.3 %Cumulative drug release vs. time (Zero order) model for PF1-PF3 
 
Fig.No:7.4 Average % drug remaining vs. time (First order model) for PF1-PF3 
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Fig.No:7.5 Average % CDR vs. SQRT time (Higuchi model) for PF1-PF3 
 
Fig.No:7.6 Average log % CDR vs. log time (Peppas model) for PF1-PF3 
7.3.9.2.Release kinetic data for polymer gum formulation: 
y = 35.562x - 34.778 
R² = 0.9741 
y = 20.033x - 10.102 
R² = 0.9988 
y = 27.788x - 23.305 
R² = 0.9543 
0
20
40
60
80
100
120
140
160
0 1 2 3 4 5 6
%
 C
U
M
U
LA
T
IV
E
 D
R
U
G
 R
E
LE
A
SE
  
  
SQRT TIME  
HIGUCHI MODEL 
PF1 PF2 PF3 Linear (PF1) Linear (PF2) Linear (PF3)
y = 0.993x + 0.9118 
R² = 0.9957 
y = 0.665x + 1.0561 
R² = 0.9912 
y = 0.9282x + 0.8797 
R² = 0.9724 
0
0.5
1
1.5
2
2.5
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6
LO
G
 %
 C
U
M
M
U
LA
T
IV
E
 D
R
U
G
 R
E
LE
A
SE
  
LOG TIME 
PEPPAS MODEL 
PF1 PF2 PF3 Linear (PF1) Linear (PF2) Linear (PF3)
 80 
 
Release kinetic data for gum formulations tabulated in Table no 7.15 and   zero-
order plot (Figure no 7.7 and 7.8), first-order plot (Figure no 7.9 and 7.10),Higuchi plot 
(Figure no 7.11 and 7.12 ) and Korsmeyer–Peppas plot (Figure no 7.13 and 7.14). The data 
of various models reviewed that formulations followed Peppas model with n value more 
than 0.5 and thus release can be concluded as non Fickanian diffusion. All the formulations 
followed zero order release kinetics. 
Table no 7.15: Release kinetics data of all the formulations 
 
FORMLN. 
CODE 
Mathematical models (kinetics) 
Zero 
order 
(R) 
First 
order 
(R) 
Higuchi 
(R) 
Korsmeyer-Peppas 
N (R) 
F1 0.9902 0.9778 0.9919 0.5559 0.9841 
F2 0.9927 0.9382 0.976 0.6024 0.971 
F3 0.9992 0.9564 0.9877 0.5619 0.9773 
F4 0.987 0.9465 0.981 0.7373 0.9768 
F5 0.9736 0.9704 0.9911 0.5971 0.9895 
F6 0.9884 0.9521 0.9832 0.6608 0.9945 
F7 0.9795 0.9771 0.9913 0.5358 0.9899 
F8 0.9919 0.9417 0.9659 0.5299 0.961 
F9 0.983 0.9363 0.9653 0.6776 0.9832 
F10 0.9794 0.9441 0.9696 0.6479 0.983 
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Fig.No:7.7 % cumulative drug release vs. time (Zero order model) for F1-F5 
 
 
Fig.No:7.8 % cumulative drug release vs. time (Zero order model) for F6-F10 
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Fig.No:7.9 Average log % drug remaining versus time (First order model) for 
F1-F5 
 
Fig.No:7.10 Average log % drug remaining versus time (First order model) for F6-F10 
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Fig.No:7.11.Average % CDR versus SQRT time (Higuchi model) for F1-F5 
 
Fig.No:7.12. Average % CDR versus SQRT time (Higuchi model) for F6-F10 
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Fig.No:7.13. Average log % CDR versus log time (Peppas model) for F1-F5 
 
 
Fig.No:7.14 Average log % CDR versus log time (Peppas model) for F6-F10 
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7.3.10. In vitro mucoadhesive strength: 
In vitro mucoadhesive strength was carried out by using self-fabricated 
instrument. Results for in vitro mucoadhesive strength and force of adhesion were 
shown in Table no.7.16 
Table no: 7.16: mucoadhesive strength of preliminary formulations 
Formulation 
code 
Mucoadhesive strength 
(g) 
Mucoadhesion force 
(N) 
PF1 23.510 2.305861 
PF2 21.443 2.103129 
PF3 24.666 2.419241 
 
Table no: 7.17: mucoadhesive strength of polymer gum formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation code Mucoadhesive strength (g) Mucoadhesion force 
(N) 
F1 23.471 2.302036 
F2 22.300 2.187184 
F3 22.720 2.228378 
F4 21.350 2.094008 
F5 20.580 2.018486 
F6 23.890 2.343131 
F7 22.576 2.214254 
F8 22.680 2.224454 
F9 24.053 2.359118 
F10 24.670 2.419634 
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7.3.11. Stability study: 
The accelerated stability studies were carried out according to ICH guidelines. 
Optimized formulations F6 and F9 were packed in amber color bottle and aluminum foil 
laminated on the upper part of the bottle and these packed formulations were stored in ICH 
certified stability chambers. Maintained at 400C ± 20C and 75 % RH ± 5 % (zone III 
conditions as per ICH Guidelines) for 3 months. The tablets were evaluated before and after 
one month for change in appearance, the drug content and in vitro release. 
After a period of one month, the samples were observed for any change on 
appearance. It was observed that tablet was devoid of any change in color or appearance of 
any kind of spot on it. It was also noted that tablet was free of any kind of microbial or fungal 
growth or bad odor. The formulation batch showed circular shape with no cracks. The drug 
content of the formulation F9 was found to be 97.83 %,  97.19% and 96.92 %  at interval of 
30 days respectively and formulation F10 was found to be 97.89%, 96.93% and  96.69 % at 
internal of 30 days respectively. The %CDR of formulation F9 was found to be 94.16% , 
93.98% and 93.82 % at interval of 30 days respectively and the %CDR of formulation F10 
was found to be 94.06%, 93.91% and 93.76 % at interval of 30 days respectively. The % 
CDR of formulation F9 and F10 were found to be Result show there was slight decrease in 
drug content but difference is insignificant. 
TablTable  no 7.18: Stability study for F9 
T
a
b
l 
 
Table no 7.19: Stability study for F10 
Time (days) Physical appearance Drug content % CDR 
30 No change 97.89% 94.06 
60 No change 96.93% 93.91 
90 No change 96.69 % 93.76 
 
Time (days) Physical appearance Drug content % CDR 
30 No change 97.83% 94.16 
60 No change 97.19% 93.98 
90 No change 96.92% 93.82 
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8. CONCLUSION 
The present study has been a satisfactory attempt to formulate mucoadhesive drug 
delivery system of gliclazide, an orally administrated anti-diabetic drug with a view of 
improving its oral bioavailability and giving sustained release of the drug for prolonged 
period of time.    
From the experimental results it can be concluded that, 
1. Mucoadhesive drug delivery systems of gliclazide can be prepared by direct 
compression method using various polymers like Chitosan, Xanthan gum, and Moringa 
gum 
2. A suitable method of analysis of drug by UV spectrophotometry was developed. 
Gliclazide showed maximum absorption at a wavelength 229 nm in pH 1.2 buffer (0.1N 
HCl). The value of regression coefficient (r2) was found to be 0.999, which showed linear 
relationship between concentration and absorbance. 
3. IR spectroscopic studies indicated that there is no drug-polymer interaction in the 
prepared formulations.  
4. On the basis of prepared preliminary formulations, final formulations were formulated 
using combinations of two or three natural polymers. 
5. All the prepared tablet formulations were found to be good without capping and 
chipping. 
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6. From this study, it was concluded that as the concentration of gum increases the 
swelling index also increases. Xanthan gum found more swelling as compare to other 
polymers. The increasing order of swelling is  Moringa gum>Xanthan gum > chitosan. 
7. All most of the designed formulations of gliclazide Mucoadhesive Drug Delivery 
Systems displayed zero order release kinetics, and drug release follows non-Fickanian 
diffusion mechanism. 
8. From this study, it was concluded that as the concentration of gum increases the in vitro 
mucoadhesive strength also increases. Chitosan showed greater mucoadhesive strength. The 
increasing order of mucoadhesive strength is Chitosan > Xanthan gum > Moringa gum. 
9. Short-term stability studies of optimized formulations F9 and F10 indicates, that there 
are no significant changes in drug content and dissolution parameter values after 1 month 
storage at 400C ± 20C and 75 % RH ± 5 %.  
 
SCOPE FOR FURTHER STUDY: 
 The work can be extended for its in vivo studies for in vitro-in vivo correlation and 
gamma Scintigraphy and various in vivo studies. 
 The formulation of mucoadhesive drug delivery system can be tried with other 
natural gums, synthetic gums and their combinations.  
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9. SUMMARY 
Gliclazide is extensively used in patients with type 2 diabetes mellitus. Gliclazide is 
readily absorbed from the gastrointestinal tract. It is extensively bound to plasma proteins. 
The half-life is about 10 to 12 hours. Gliclazide is extensively metabolized in the liver to 
metabolites that have no significant hypoglycemic activity. Metabolites and a small amount 
of unchanged drug are excreted in the urine.  The usual initial dose is 40 to 80 mg daily, 
gradually increased, if necessary, up to 320 mg daily.  
In the present study, an attempt was made to design and optimize GMDDS of 
Gliclazide using natural polymers like Chitosan, Xanthan, and Moringa gum 
Drug and polymers were subjected for the compatibility study using FTIR, which 
suggested that there is no interaction between the drug and polymer. 
The tablets were prepared by direct compression technique. Three batches of 
preliminary formulations were designed and from the results of evaluation data, final 
formulations were selected for further study by using natural polymers.  
Further development of mucoadhesive tablets of gum formulations were carried out 
by using combinations of various natural polymers. The prepared mucoadhesive formulations 
were evaluated for hardness, friability, weight variation, drug content uniformity, in vitro 
swelling study studies, in vitro drug release pattern, in vitro mucoadhesive strength, short-
term stability and drug-excipients interaction.  
The results are quoted in different section of the result and discussion. 
Various evaluation parameters, we can summarize: 
 From IR and physical observation it was observed that there was no significant Drug- 
Excipient interaction. Melting point of Gliclazide was found to be in range between 
177-179 0C. 
 The bulk density and the tapped density for all the formulations varied from 
0.4284±0.005 to 0.4679±0.003 gm/cm3 and 0.4763±0.011 to 0.5361±0.0105gm/cm3 
respectively. 
  The angle of repose data for all the formulations ranges from 180.92’±0.313 to 
250.37’±0.171. Hausner’s ratio of all formulations ranges from 1.1098±0.027to 
1.1965±0.017. The results of the Carr’s consolidation index of all the formulations 
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ranges from 09.80 % to 16.42 %.  
 Tablet thickness (n=3) were almost uniform in all the formulations and values for 
tablets ranged from 2.839± 0.026 to 3.129± 0.043 mm. The weight uniformity of tablets 
ranged from197.9± 1.786 to 199.8± 1.259 mg.  
 The hardness of all formulations was in the range of 4.97± 0.032 to 6.93± 0.133 
kg/cm2.      
The values of friability of all formulations ranged from 0.67 to 0.92%. 
 The % drug content of all the formulated tablets were found within the limit. % drug 
content value of gliclazide was within 94.89± 0.886% to 97.89± 1.009%. 
 All three polymeric gums containing tablets shows good mucoadhesion strength as 
compare to two combinational gums containing tablets. Among all thirteen 
formulations F10 show maximum mucoadhesion strength of 2.4196and F5 shows 
lowest mucoadhesion strength of 2.0184. 
 Xanthan gum shows highest swelling index and Moringa gum shows less swelling 
index among others. 
 % cumulative drug release after 24 hrs for F9 and F10 showed 94.24±1.037, 
94.07±0.790 respectively. These two optimized formulations follows zero order with 
non fickian diffusion on the basis of regression coefficient of the kinetic data of 
cumulative drug release from the dosage form. 
 The results of accelerated stability study showed that there was no change in the 
formulation after three month. 
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